

## Curriculum Vitae

**W. Kimryn Rathmell, MD, PhD**

### **Executive Summary:**

Dr. Rathmell is the CEO of the James, Ohio State University's flagship cancer hospital and a leading cancer research institute in the United States. She previously served as the 17<sup>th</sup> Director of the National Cancer Institute (NCI), National Institutes of Health, for the United States of America. Over the course of her career, Dr. Rathmell has championed medical science, ethics in medicine, and academic and physician-scientist career development. As a prior chair of the Department of Medicine and Physician-in-Chief at Vanderbilt and president of the American Society for Clinical Investigation (ASCI), a leading cancer researcher in the NCI Cancer Genome Atlas, the Department of Defense (DOD) kidney cancer research program, and the NCI as a member of the Board of Scientific Advisors, she is an experienced leader in biomedical science nationally. Dr. Rathmell is a member of the ASCI, the Association of American Physicians (AAP), and was elected to membership to both the American Academy of Arts and Sciences (AAAS), and the National Academy of Medicine (NAM). Dr. Rathmell has pioneered basic science investigation of kidney cancer, and her work reveals the biological diversity of these tumors in addition to uncovering novel mechanisms of cancer promotion and paving the way for new therapeutics.

### **Education:**

08/1987-06/1991	BA, University of Northern Iowa, Chemistry, Highest Honors, top graduate
08/1987-06/1991	BS, University of Northern Iowa, Biology, Highest Honors
07/1993-09/1996	PhD, Stanford University, Biophysics Mentor: Gilbert Chu, MD, PhD
08/1991-06/1998	MD, Stanford University, Medicine
09/2021-12/2022	Masters of Management in Health Care, MMHC, Owen School of Management Vanderbilt University

### **Postgraduate Training:**

07/1998-06/1999	Intern, University of Chicago, Internal Medicine
06/1999-06/2000	Resident, University of Pennsylvania, Internal Medicine
06/2000-06/2004	Fellow, University of Pennsylvania, Medical Oncology
07/2001-07/2003	Postdoctoral Training, University of Pennsylvania, Mentor: M. Celeste Simon, PhD

### **Licensure and Professional Certification:**

2001-2011	ABIM 208912, Board Certification Internal Medicine (inactive)
2004-2027	ABIM 208912, Board Certification Medical Oncology (active)
2000-2003	Medical Licensure Pennsylvania Commonwealth, MT045523T (inactive)
2003-2015	Medical Licensure North Carolina Medical Board, 2003-061123 (inactive)
2015-2026	Medical Licensure Tennessee Medical Board, MD 0000053185
2016-2022	Medical Licensure Mississippi State Board, 29269
2021-2022	Medical Licensure Iowa Board of Medicine, MD-48800

2021-2022 Medical Licensure Alabama Board of Medical Examiners, MD.42999  
 2021-2024 Medical Licensure Kentucky Board of Medical Licensure, C0360

**Positions Held (chronological):**

08/2003-11/2004 Instructor, Department of Medicine, University of North Carolina at Chapel Hill  
 12/2004-10/2010 Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Department of Genetics (Secondary), UNC Chapel Hill  
 01/2011-01/2012 Graduate Faculty Member, Department of Pharmacology and Cancer Biology, Duke University  
 10/2010-06/2015 Associate Professor with tenure, Department of Medicine, Division of Hematology and Oncology, Department of Genetics (Secondary), Department of Urology (Secondary), UNC Chapel Hill  
 07/2013-06/2015 Alexander Professor for Translational Science, University of North Carolina at Chapel Hill  
 07/2015-01/2020 Cornelius A. Craig Professor, Department of Medicine, Director, Division of Hematology and Oncology, Vanderbilt University Medical Center  
 07/2019-08/2021 Deputy Director for Research Integration and Career Development, Vanderbilt-Ingram Cancer Center  
 08/2020-12/2023 Hugh Jackson Morgan Endowed Professor, Chair, Department of Medicine, Physician-in-Chief, Vanderbilt University Medical Center, (interim, 01/2020-07/2020)  
 12/2023-01/2025 Director, National Cancer Institute, National Institutes of Health—*note that this Presidentially-appointed position required relinquishment of all other appointments, boards, grants, and other interests that may be perceived as conflicts of interest to the role to advance cancer research and care for the American people. Resigned in accordance with federal statute governing political appointees.*  
 05/2025-present Chief Executive Officer, Alfred G. James Cancer Hospital and Richard J. Solove Research Institute of the Ohio State University Wexner Medical Center, inaugural holder of the Jeri B. Block and Robert Schottenstein Chair in Cancer Research

**Honors and Awards (Reverse chronological):**

2025 Arthur Kornberg and Paul Berg Distinguished Alumni Award, Stanford  
 2025 Hologic, Inc. Endowed Women Who Conquer Cancer Award  
 2025 UChicago Medical & Biological Science Distinguished Alumni Award  
 2025 ASCI Stan Korsmeyer Award for Excellence in Mentorship  
 2025 American Cancer Society, Medal of Honor  
 2023 Doris Duke Charitable Foundation, Paragon Award  
 2023 American Academy of Arts and Sciences, Elected Member  
 2023 Fellow of the American Society of Clinical Oncology (FASCO)  
 2023 2023 Advanced Practice Ambassador, Vanderbilt University  
 2022 National Academy of Medicine, Elected Member  
 2022 Charles R. Park Award for Basic Research Insights into Human Physiology

2021	American Association of the Advancement of Science, Elected Fellow
2020	AACR Team Science Award (the Cancer Genome Atlas)
2019	Eugene P. Schoenfeld Award for Outstanding Contributions in Kidney Cancer
2019	Louisa Nelson Award, honoring women of achievement, inspiration, and vision in Nashville
2018	Association of American Physicians (AAP), Elected Member
2018	AACR-Kure-IT Award for Immunotherapy in Kidney Cancer
2017-2021	ASCI Vice President, President-elect 2018, President in 2019
2015	Leland Wilson Chemistry Endowed Lectureship, University of Northern Iowa
2014	UNC ACCLAIM Leadership Development Program
2014	Alpha Omega Alpha (AOA) induction
2012	Ruth and Philip Hettelman Award for Scholarly Achievement
2011	American Society of Clinical Investigators (ASCI) induction
2011	Award for Outstanding Achievement, 14th World Congress on Cancer
2010	AACR Landon INNOVATOR Award for Personalized Medicine
2010	ASCO Leadership Development Award
2009-2017	Best Doctors in America
2006-2009	Doris Duke Clinical Scientist Development Award
2006-2007	American Cancer Society Research Scholar Award
2004, 2008	Lineberger Clinical/Translational Medicine Research Award
2004	UNC School of Medicine Junior Faculty Grant
2004-2008	Forbeck Forum Scholar Award
2003-2008	National Cancer Institute Career Development Award K08 CA98410
2003-2005	V Scholar Award, The V Foundation for Cancer Research
1996-1998	Medical Scientist Training Program, Stanford University
1996	PEO Scholar Award
1994-1996	Howard Hughes Predoctoral Fellowship, Stanford University
1992-1997	Ruth G. White PEO Scholarship
1991-1994	Medical Scholars Research Grant, Stanford University
1991	Purple and Old Gold Award, University of Northern Iowa, Chemistry (Top Graduate in a Major)
1991	Graduate with Highest Honors, University of Northern Iowa
1990	J.S. Latta Biology Research Grant, University of Northern Iowa
1989	J.S. Latta Biology Scholarship, University of Northern Iowa
1987-1991	Presidential Scholar, University of Northern Iowa

### **Teaching Activities:**

#### Primary Research Mentorships

<b>Mentee</b>	<b>Date</b>	<b>Mentee Position</b>	<b>Honors/Awards/Current Position</b>
Will Becker, PhD	2024-2025	Staff Scientist	Current: NIH Staff Scientist
E Jennings, PhD	2023-2025	Post-doc	VU Destination Biochemistry Awardee, T32CA009582

			Current: NIH Staff Scientist
S Baril, MD	2022-2024	Fellow/Post-doc	T32CA119925 Current: Pediatric Oncologist
L Vlach	2022-2024	PhD student	T32CA009592 Current: PhD Student with F.Mason
E Arner, PhD	2021-2024	Post-doc	F99/K00 CA253718 Current: Postdoc with J. Rathmell
D Gaines, MD PhD*	2021-2023	Post-doc	Holmen Pathway Fellowship Current: Asst Professor, VUMC
M Wolf	2019-2024	PhD student	F31 CA261049 2021 Dean's Award Winner Current: Postdoc, VUMC
Z Bacigalupa, PhD	2018-2023	Post-doc	T32 CA119925 Current: Res. Asst. Prof., VUMC
S Norris, PhD	2017-2018	Post-doc	T32 CA009582 Current: Scientist, Calico Labs
B Reinfeld, PhD	2017-2022	MSTP student	T32 GM007347 F30 CA247202 Current: Med Resident, UCLA
A Lim, MD PhD	2016-2021	MSTP student	T32 GM007347, AOA, Top Poster, American College of Surgeons Current: Radiology Resident BWH
E Terzo, PhD*	2016-2018	Post-doc	T32 CA119925 Current: Scientist, Constellation
F Mason, PhD	2016-2023	Post-doc	KCA YIA, KCRP DOD Idea Award Current: Asst Professor, VUMC, R01 funded
J Weyandt, PhD	2016-2018	Post-doc	T32 CA119925 Current: Staff Scientist, LabCorp
K Beckermann, MD PhD	2015-2018	Fellow/Post-doc	CRI Irvington Fellowship K12 CA090625 Current: Asst Professor, VUMC, DOD funded
A de Cubas, PhD*	2015-2022	Post-doc	T32 CA009582, ACS Postdoctoral Fellowship, K01 CA245231 Current: Asst Professor, MUSC
Y-C Chiang, PhD	2014-2017	Post-doc	T32 CA009156 Current: Staff Scientist, CRO Novella, Adjunct UNC
A McRee, MD	2015-2015	Fellow/Post-doc	Faculty at UNC, promoted to assoc prof., now Senior Medical Director Janssen
S Sundaram, PhD	2014-2015	Post-doc	Current: USDA, Fargo, NC

Z Debebe, PhD*	2012-2014	Post-doc	Lineberger Postdoc T32 CA009156 Merck Postdoc Fellowship Current: Scientist, KBI Pharma
H Horne, PhD	2011-2012	Post-doc	Current: Lead Scientist, KBI Pharma
C Fahey, MD PhD	2012-2017	MSTP student	CTSA KL2 Program, UPenn T32 GM008719, T32 CA07134 F30 CA192643-01 Gertrude Elion Award PEO Scholar Award Onc Fellow, VUMC, T32 CA217834 Current: Asst Prof, UNC
S Brooks, PhD MPH*	2011-2015	PhD student	UNC Toxicology T32 ES007126 HHMI Med-Grad Translational Medicine Program NIH Postdoc, MPH Current: Translational Safety Scientist, Amgen
S Haake, MD, PhD	2011-2012 2017-2022	Resident	K08 CA241351 (primary mentor) Current: Asst Professor, VUMC
K (Hacker) Gessner, MD PhD	2010-2014	MSTP Student	T32 GM008719, T32 GM007092 T32 CA071341 Gertrude Elion Award Current: Asst Professor, UNC
A Arreola, PhD*	2009-2014	PhD student	F31 CA154080 T32 Training Grant GM007092 Current: Lead Cytogenetic Analyst, Lab Corp
N Rasmussen, PhD	2008-2013	PhD student	T32 HL069768 Current: Res Asst Prof Texas A&M
CL Cowey, MD	2007-2009	Fellow	T32 HL007149 Current: Faculty Baylor University Sammons Cancer Center, SU2C Melanoma PI
M DeSimone, PhD	2007-2011	PhD student	HHMI Med-Grad Translational Medicine Award Current: Regeneron, Scientist
AR Brannon, PhD	2006-2011	PhD student	T32 CA071341 Postdoc: MSKCC, Cancer Genomics UNC Grad Student Merit Award NSF Award Honorable Mention Current: Director, Clinical Bioinformatics, MSKCC

CM Lee, MD PhD	2005-2009	MSTP student	Med/Peds resident, Duke NIEHS F30 ES 015248 Keystone Travel Award PEO Scholar Award Current: Assoc Prof, Wash U.
T Wright, PhD*	2005-2010	PhD student	F31 CA132543 Biotechnology Institute Minority Fellows Program UNC Lineberger Grad Award Postdoc: Duke Cancer Biology Current: Faculty, Salk Institute, Director of Postdoctoral Affairs
S Chen, MD PhD	2004-2011	Post-doc	VHL Family Alliance Fellowship Current: Research Assoc Prof. UNC

### Student Summer Preceptorships

- Vania Shi, Vanderbilt University (2022), Vanderbilt junior
- Whitney Brown, Vanderbilt University (2020-2022), now in med school, IU
- Edith Amason, Seewanee College (2019-2020), now in PhD training, UPenn
- Stephen Himmelberg, Washington and Lee University (2015), completed MD, UNC
- Zachary Husk, University of North Georgia, (2013), completed PhD, now CEO Qitek labs
- Natalie Sutton, NC Central University (2012), MPH, now Clinical Project Manager at IQVIA
- Nzingha Saunders, NC Central University (2011), completed DO, now a resident
- Melissa Ruiz, William and Mary (2007), completed MD, Virginia Commonwealth
- Kate Hacker, Dartmouth College (2006), MSTP at UNC, now faculty UNC
- Ray Stadiem, UNC medical student (2005), Resident/Chief Resident Internal Medicine, Northwestern Univ. Current: Faculty, Carolinas Medical Center, Charlotte, NC

### Undergraduate students

- Shreeti Amin (Vanderbilt 2022-2023), continuing undergraduate
- Amisha Mittal (Vanderbilt 2023-Administrative Intern), went on to MD/MBA at U Miami
- Whitney Brown, Biochemistry (Vanderbilt 2019-2022), went on to medical school at IU
- Colby Williams, (Vanderbilt 2018-2020), went on to medical school at UT Memphis
- Anuj Bhatia, (Vanderbilt 2018-2020), went on to business school
- Robert Hapke, Biochemistry (Vanderbilt 2017-2020) \*Winner, most outstanding student in Biochemistry, 2019, 2020, went on to MSTP training at University of Pennsylvania
- Armando Corona, Postbac program, UNC Pembroke (2014-2015), went on to PhD, Duke
- Sudarshan Mohan, Biostatistics/Biology (UNC 2011-2015), went on to medical school, EVMS
- Oishee Sen, Anthropology (UNC 2010-2014), went on to medical school, UNC
- Alex Karamlegas, Biology, pre-med (UNC 2008-2009), went on to medical school, VCU
- Natalie Carraway, Chemistry, (UNC 2003-2005), research technician, Duke

### Graduate Supervision, Thesis Committees

- Gwenyth Joseph, Rachele Johnson Lab, Cancer Biology (co-mentor)

- Jessica Roetman, Mary Philip Lab, PhD Cancer Biology 2023
- Alex Pfannenstien, Ian Macara Lab, PhD Cell Biology 2023
- Juan Rojas, Paul Dayton Lab, PhD Engineering 2018
- Zhi Hu, Vicky Bautch Lab, PhD Genetics 2016
- Aminah Dal, Ian Davis Lab-PhD Genetics 2016
- Marybeth Anderson, Jen Jen Yeh Lab, PhD Genetics 2016
- Michael Iglesia, Chuck Perou Lab, PhD Genetics 2015
- Stephen McDaniel, Brian Strahl Lab-PhD Biochemistry 2016
- David Wei, Buddy Weissman Lab, PhD Toxicology 2014
- Alicia Greenwalt, Cyrus Vizieri Lab-replaced on move to Vanderbilt
- Kate Coleman, Jeanette Cook Lab, PhD Genetics 2015
- Isaac Chan, Al Baldwin Lab/Anna Mae Diehl Lab, PhD Genetics 2012
- Sean Bailey, William Kim Lab, PhD Genetics 2014
- Christina Lamb, Toxicology program, PhD Toxicology 2013
- Jessica Sorrentino, Ned Sharpless Lab, PhD Toxicology 2013
- Becky Sinnot, Angelique Whitehurst Lab, PhD Pharmacology 2013
- Yolanda Whang, Mohanish Deshmukh Lab, PhD Cell Biology 2009
- Kim Peterman, Ned Sharpless Lab, PhD Genetics 2008
- Aaron Thorner, Chuck Perou Lab, PhD Genetics 2010
- Sara Hanna, William Kim Lab, PhD Genetics 2013
- Sarah Stein, Al Baldwin Lab, PhD Biology 2012
- George Chao, Chuck Perou Lab, PhD Genetics 2012
- Adam Kimple, Mohanish Deshmukh Lab, PhD Genetics 2011
- Brian Lew Teng, Anthony Means Lab, Duke University, PhD Pharmacol 2011

#### Vanderbilt Junior Faculty Mentoring (formal assignment)

- Dr. Travis Osterman, Hematology and Oncology – Clinical Informatics (K12), now associate professor, R21 funded, Director Cancer Clinical Informatics, VICC
- Dr. Naira Baregamian, Surgical Oncology (BWF SPIRE Scholar, VFRS), now associate professor
- Dr. P. Brent Ferrell, Hematology and Oncology (K23), now Mark Foundation and VA Merit Award funded
- Dr. Vivian Weiss, Pathology (K08), now associate professor, R01 funded
- Dr. Scott Haake, Hematology and Oncology (K08, K12), now DoD funded
- Dr. Katy Beckermann, Hematology and Oncology (CRI-Irvington, K12), now DoD funded
- Dr. David Chism, Hematology and Oncology (ASCO LDP)
- Dr. Dolly Ann Padovani-Claudio, Ophthalmology (K08) – now associate professor, R01 funded
- Dr. Doug Johnson, Hematology and Oncology (K23) – now associate professor, R01 funded
- Dr. Jennifer Green, Hematology and Oncology – Director, VUMC Hemophilia 340B Program
- Dr. Charles Caskey, Biomedical Engineering – now associate professor, R01 funded
- Dr. Elizabeth Davis, Hematology and Oncology – now associate professor, Director, clinical trial office

#### UNC Junior Faculty Mentoring (formal assignment)

- Dr. Emily Chang, MD, Nephrology – Associate Professor

- Dr. Nate Hathaway, PhD, Medicinal Chemistry – Associate Professor
- Dr. Qing Zhang, PhD, Pathology – Professor (now at UTSW)
- Dr. Stephanie Sarantopoulos, MD-PhD, Medicine/Immunology – Professor (now at Duke, Hematology Division Director)
- Dr. Kristy Richards, PhD-MD, Medicine/Genetics (*deceased*)
- Dr. Carey Anders, MD, Medicine – Professor, interim Division Director, Oncology (Duke)
- Dr. James Coghill, MD, Medicine/Immunology – Associate Professor

### **Professional Organizations:**

#### *American Society of Clinical Investigation*

- Associate Editor, Journal of Clinical Investigation (2012-2017)
- Councilmember, Secretary-Treasurer (2014-2017)
- Publications Committee (2017-2020, chair 2019)
- Development Committee (2018-2023, chair 2018)
- Advocacy Committee (2017-2018, founder, chair 2017)
- Harrington Prize Selection Committee (2019-2021)
- Vice President (2017-2018)
- President Elect (2018-2019)
- President (2019-2020)
- Seldin-Smith Award Selection Committee (2021)

#### *American Association for Cancer Research*

- Member 2003-present
- Faculty, AACR Molecular Biology in Clinical Oncology, Aspen, CO (2017, 2021, 2022)
- AACR Daniel D. Von Hoff Award Committee (2022-2023)

#### *American Association for the Advancement of Science*

- Member 2015-present
- Fellow, elected 2021

#### *American Society of Clinical Oncology*

- Member 2001-present
- ASCO Career Development Committee 2006-2009
- ASCO Cancer Education Committee, Fellows and Faculty Program 2008
- ASCO Membership Committee 2009
- ASCO Leadership Development Program 2010-2011
- ASCO Ethics Committee 2011-2014
- ASCO Education Committee, Tumor Biology 2014-2017 (track leader)
- ASCO Nominating Committee (elected position, chair) 2018-2020
- ASCO Guidelines, Metastatic RCC (co-chair) 2020-2021
- ASCO Special Awards Selection Committee 2021-2024

*American Physician Scientist Association (APSA)*

- Board of Directors (elected position, 2023)

*Alliance for Clinical Trials in Oncology*

- Alliance Scholar Selection Committee (2014)

*Burroughs Wellcome Foundation*

- CAMS Scientific Advisory Committee (2019-2023)
- Diversity Pipeline Workshop (2019)

*Damon Runyon Cancer Foundation*

- Clinical Research Investigator Award Review Committee (2020-2023)

*FASEB*

- Board of Directors, Advisor (2017-2018)

*Forbeck Foundation*

- Scientific Board of Directors (2021-2023, 2025-present)
- Scholar Award Meeting Chair, Lake Geneva, WI (2015)
- Focus meeting organizer “International Colloquium on Renal Medullary Carcinoma Nashville, TN (2016)
- Focus meeting organizer “Histone biology in cancer” (2022)

*Foundation for the NIH*

- Paul-Gallin Trailblazer Prize for Physician-Scientists, Award Committee (2025-present)

*Keystone Symposia*

- Board of Directors (2023)
- Personnel Committee (2023-2023)

*KC CURE*

- Scientific Advisory Committee (2016-2021)

*Kidney Cancer Association*

- Annual meeting, scientific programming committee (2013-16)
- KCA Southeast Region Patient Survivor Conference (2013, 2014 Organizer)
- KCA MidSouth Patient and Survivor Conference (2016, 2017 Organizer)
- KCA Medical Steering Committee (2019-2023)
- Women in Kidney Cancer (co-chair, 2019-2023)

*MSKCC Paul Marks Prize*

- Selection committee (2019-2023, 2025-present, Chair)

*National Academy of Medicine (NAM, elected 2022)*

- NASEM Workshop on Addressing Resistance in the Development of Cancer Immune Modulator Therapeutics. Program Committee (2022)

*National Urology Research Agenda (NURA)*

- Program member (2017)

*RMC Alliance*

- Founding member and co-chair (2016-2023)
- Scientific Program Organizing Committee, first annual meeting (2017)

*Society of Urologic Oncology*

- Annual meeting, Kidney cancer program task force (2011, 2013, 2014)
- Annual meeting, Kidney cancer program chair (2012)
- Annual meeting, Scientific Planning Committee (2016, 2017)

*VHL Family Alliance*

- Clinical Trials Task Force (2012-2014)
- VHLA Clinical Advisory Council (2014-2019)
- VHL CGIP Research Proposal Committee (2016-2019)
- VHL Alliance Annual Meeting Organizing Committee (2018)
- VHL Alliance Research Council (2020-2023)

**Professional Activities (Academic Service):**

*Within Vanderbilt University*

- Athletics Committee (2023)
- Department of Health Policy Chair Search Committee (2023)
- Capacity Command Center (2022-2023)
- Link Building Oversight Committee (2022-2023)
- Blood Allocation Task Force (2022, chair)
- Dean, Biomedical Sciences, Search Committee (2021-2022), recruited Dr. John Kurian
- Vice President for Access, Search Committee (2021), recruited Dr. Jennifer DeBruler
- Department of Biomedical Informatics Chair Search Committee (2021, chair), recruited Dr. Peter Embi
- VMG Finance Committee (2020-2023)
- VMG Board (2020-2024)
- Executive Faculty Committee (2020-2023)
- Medical Center Medical Board (2020-2023)
- Vanderbilt Transgender Medicine Initiative (2019-2023)
- VU-VUMC Trans-Institutional Program Committee (2017-2023), Task force (2020)
- Radiation Oncology Chair Search Committee (2019-2020)
- Cardiovascular Medicine Director Search Committee, Co-Chair (2020)
- Vanderbilt Cancer Committee (2019-2023)
- Grievance Committees, Faculty Senate (2019, 2020)

- Search Committee, Department of Surgery Chair (2018)
- Faculty Affairs Promotions Committee (2017-2019)
- Grievance Committee, Faculty Senate (2018)
- Cancer Biology Program Executive Committee (2017-2019)
- Vanderbilt Faculty Research Scholar Selection Committee (2017-2020)
- Vanderbilt-Ingram Cancer Center, Cancer Education Advisory Committee (2017-2023)
- Vanderbilt-Ingram Cancer Center, Executive Leadership Committee (2015-2023)
- Vanderbilt University Medical Center, Strategic Planning Committee-Research Team (2018)
- Vanderbilt Department of Medicine Executive Committee (2015-2023)
- Vanderbilt Department of Medicine Compensation Plan Committee (2016-2017)
- Vanderbilt University Medical Center Strategic Planning Committee (2016)
- Vanderbilt-Ingram Cancer Center, Clinical Trials Office Steering Committee (2015-2020)
- Program Director and Steering Committee Leader, Vanderbilt Hemophilia Treatment Center (2017-2020)
- Medical Director, Vanderbilt Hemophilia Treatment Center (2016-2017)
- Vanderbilt MSTP College Advisor (Avery-Cohen College, 2016-2021)
- Vanderbilt Limited Submission Opportunity Reviewer (2016-2019)
- Medical Director, Hemophilia Treatment Center (2016-2017), Program Director (2017-2020)
- Oncology Care Model Steering Committee (2016-2020)
- Oncology Care Model Psycho-oncology Implementation Committee, chair (2016-2020)
- Oncology Clinical Leadership Committee (2015-2020)
- Hematology and Oncology Leadership Committee Chair (2015-2020)
- Hematology and Oncology Fellowship Steering Committee (2015-2020)

*Within UNC-Chapel Hill*

- UNC Lineberger Cancer Center, Associate Director for Education and Training (2014-2015)
- UNC Lineberger Cancer Center, Faculty Director Tissue Procurement (2014-2015)
- School of Pharmacy, Faculty Search Committee (2014), Dr. Stephen Frye, Chair
- Department of Genetics Faculty Search Committee (2013), Dr. Rosann Farber, Chair
- Research Imaging Center Faculty Search Committee (2013), Dr. Weili Lin, Chair
- UNC MD-PhD program, Director for Translational Research (2012-2015)
- HHMI Translational Medicine Med<sup>2</sup>Grad Certificate Program, Clinical Director (2010-2015)
- Translational Medicine Med<sup>2</sup>Grad External Advisory Committee (2016-present)
- Translational Medicine, New PhD program planning committee (2011-2014)
- UNC Hospital Strategic Planning Committee—subgroup leader (2011)
- Biomedical and Biological Science Program Graduate students Admission Committee, Member (2010-2011)
- Lineberger Faculty Search Committee (2010-2013), member, Dr. Al Baldwin, chair
- Oncology Junior Faculty Mentoring Program (2010-present), Director
- Core Leadership Team, HHMI Med-into-Grad Program (2009-2014), co-director
- Medicinal Chemistry Faculty Search Committee (2012), member, Dr. Jian Liu, Chair
- Senior Nanotechnology Faculty Search Committee (2009-2011), member, Dr. Rudy Juliano, Chair

- Sociology/Psychiatry Faculty Search Committee (2009-2010), member, Drs. Don Baucom and Ken Bollen, Co-chairs
- Animal Models Core Committee, (2009-2015), member
- Experimental Imaging Faculty Search Committee (2009), Dr. Weili Lin, Chair
- UCRF Cancer Genetics Theme Team (2008-2010), Dr. Daniel Pomp, Chair
- Genetics Faculty Search Committee (2008-2010), member
- Sheps Center, Grant Review Committee (2008), member
- Initiative to Maximize Student Diversity Task Force (2007), member
- Lineberger Translational Grant Review Committee (2006-2008, 2010), member, (2011, 2015), chair
- UNC Initiative to Maximize Student Diversity Committee, (2006-2013), member
- UNC Protocol Review Committee, (2005-2010, 2013), member
- Genetics and Molecular Biology Admissions Committee, (2005-2008), member
- UNC MD/PhD Training Program Executive Board, (2004-2015), member
- UNC MD/PhD Training Program Admissions Committee (2004-2015), member

#### *Outside institutions*

- Dana Farber Cancer Institute
  - External Advisory Committee, SPORC in Kidney Cancer—PI: David McDermott
  - Dana Farber K12 Advisory Committee
- University of Pennsylvania
  - External Advisory Committee, T32 in Oncology – PI: Ivan Maillard
- University of Pittsburgh Medical Center (inactive)
  - External Advisory Committee, P01 on endothelial biology—PI: Michael Lotze
- University of Chicago
  - External Advisory Committee, SOAR Program – PI: Funmi Olopade
  - External Advisory Committee, T32 in Oncology – PI: Funmi Olopade
- MD Anderson Cancer Center
  - External Advisory Committee, T32 in Oncology – PI: Michael Davies
- Emory University
  - External Advisory Committee, K12 in Oncology – PI: Christopher Flowers
- Medical University of South Carolina
  - External Advisory Committee, K12 in Oncology – PI: Craig Lockhart
- University of California at Davis
  - External Advisory Committee, K12 in Oncology – PI: Primo Lara
- Northwestern Lurie Cancer Center
  - External Advisory Committee, T32 in Oncology – PI: Hidayatullah G. Munshi
- University of North Carolina
  - External Advisory Committee, T32 in Molecular Medicine – PI: JenJen Yeh

#### Grant review study sections (non-NIH)

- American Cancer Society, TBG Study Section, Permanent Member (2010-2017)
- Department of Defense
  - CDMRP Integration Panel, permanent member (2010-2013)

- CDMRP Kidney Cancer Research Program-Stakeholders Meeting (2017)
- CDMRP Kidney Cancer Research Program Integration Panel (2017-)
- CDMRP Kidney Cancer Research Program Integration Panel, chair (2018-2021)
- Burroughs Wellcome Fund (noted above)
- Damon Runyon Cancer Foundation (noted above)
- Dutch Cancer Society, ad hoc reviewer (2010-2012)
- Florida Department of Health, ad hoc reviewer (2010)
- Federal Drug Administration, Orphan Products program, ad hoc reviewer (2009-2012)
- Italian Ministry of Health, ad hoc reviewer (2009-2012)
- Terry Fox Cancer Research Institute-Program Project Reviewer (2016)

#### National Institutes of Health

- NCI Board of Scientific Advisors (2018-2023)
- NCI Provocative Questions Basic Science Workshop (2019)
- CSR Fellowship Panel Oncological Sciences F09B (2015-2018)
- NIH BMCT-C Ad Hoc member (2013)
- NIH NCI-J Ad Hoc member (2013, 2014, 2017)
- NIH NCI-F09 Ad Hoc member (2015)
- NIH MONC Ad Hoc member (2016)
- NIH SEP 6 Review Committee, ZCA1 SRB-K (O1) (2017)
- External Reviewer Urologic Oncology Branch, Genitourinary Oncology Branch (2015)
- NanoMedicine Roadmap Initiative, External Advisory Board (2011-2014)
- NIH Kidney Cancer Task Force (2011-present)
- The Cancer Genome Atlas Network-Tissue Source Site, Disease Advisor (2009-2015)
- The Cancer Genome Atlas-Kidney Cancer Disease Working Group (2009-2011)
- The Cancer Genome Atlas-Kidney Clear Cell Cancer Analysis Working Group (AWG)
  - RNA analysis and clinical data leader (2011-2013)
  - Papillary Kidney Cancer, AWG, RNA analysis and clinical data (2013-2014)
  - Pheochromocytoma and Paraganglioma AWG, disease expert, writing group (2014-2017)
  - Cholangiocarcinoma AWG (2014-2017)
- The Cancer Genome Atlas-Chromophobe Kidney Cancer AWG, Co-chair (2012-2014)
- The Cancer Genome Atlas-PanRCC AWG, Co-chair (2015-2018)
- **Selected committee activities in the role of NCI Director:**
  - Institute and Center Directors (2023-2025)
  - NIH CARE for Health Board of Directors (2024-2025)
  - NIH Climate Change and Health Executive Committee (2024-2025)
  - NIH Clinical Center Governing Board, chair (2023-2025)
  - NCI Scientific Program Leaders, chair (2023-2025)
  - NCI Executive Committee, chair (2023-2025)
  - NCI Equity Council, co-chair (2023-2024)

#### Manuscript Review

*New England Journal of Medicine, Nature, Nature Medicine, Nature Communications, Nature Metabolism, Nature Ecology and Evolution, Cancer Research, Clinical Cancer Research, Molecular Cancer Research, Journal of Clinical Oncology, Proc Nat Acad Sci USA, Journal of Clinical Investigation, JCI Insight, Cancer, Cancer Discovery, Molecular and Cellular Biology, Nature Reviews Clinical Oncology, PLoS Genetics, PLoS One, Journal of Urology, Urology, BMC Cancer, British Journal of Urology, European Urology, others*

#### Editorial Boards

- eLIFE, Senior Editor, 2022-2023
- Journal of Clinical Investigation, Associate Editor, Editorial Board, 2012-2017
- Journal of Clinical Investigation, Consulting Editor, 2017-2023
- JCO-Precision Oncology, Editorial Board, 2016-2023
- Cancer Research, Editorial Board, 2012-2015
- Oncology Reports, Editorial Board, 2012-2015
- Kidney Cancer, Editorial Board, 2016-2023

#### Consulting/Advising

- Aravive, Scientific Advisory Board (2019-2023)
- Bayer-Vanderbilt, Joint Steering Committee, co-chair (2020-2023)
- GE-VUMC Steering Committee (2019-2023)
- Novartis, Sales Training Consultant (2010)
- AVEO Pharmaceuticals, Clinical and Biomarker Senior Advisory Board (2009-2012)
- Wyeth Pharmaceuticals, Expert Advisory Panel (2008)
- Onyx Pharmaceuticals, Expert Clinical Advisory Panel (2006-2007)
- GSK Biomarkers Advisory Board (2011)

#### Patents/Licensure:

- Methods and Compositions for Analysis of Clear Cell Renal Cell Carcinoma. Provisional Application Serial No. 61/287,986. UNC Ref. No. 10-0073. *Relinquished*

#### Grant Support: (all grant support reassigned to new PI's in 2023)

1R01CA275082-01 (MPI K Rathmell/Dere) 07/01/2022-06/30/2027  
*Convergent Drivers of Tumor Evolution at the Mitotic Spindle*  
Goals: Our Overarching Hypothesis is that VHL and RCC-associated 3p and 5q chromatin remodelers coordinately regulate methylation of spindle microtubules to maintain genomic stability, which when defective, offers unique opportunities for therapeutic intervention.

KC210152 CDMRP (MPI K Rathmell/J Rathmell) 09/01/2022-08/31/2025  
*Metabolic Demands and Determinants in the RCC Tumor Microenvironment*  
Goals: We hypothesize that the distinct metabolic properties of different cell subsets in the ccRCC TME contribute to tumor metabolic heterogeneity (evidenced by mixed PET imaging signals) and that genetic alterations in ccRCC shape the TME and influence the metabolism and function of macrophages present in the tumor space.

R01 CA217987-01 (MPI J Rathmell/K Rathmell) 04/01/2023-03/31/2028

*Metabolic Barriers to T Cell Activation in Clear Cell Renal Cell Carcinoma*

This grant examines the T cell response to cancer cell signals in kidney cancer.

\*Previous grant period 04/01/2018-03/31/2023, K Rathmell serves as Co-I

RA210205 CDMRP (Jonasch) 07/01/2022-06/30/2025

*Developing a Data and Tissue Sharing Platform for Von Hippel Lindau disease*

Major Goals: To create a reliable data sharing network between coordinating cancer centers, in order to rapidly enhance our understanding of vHL disease specific manifestations and accelerate the development of better management strategies for this rare hereditary disorder.

Role: Co-I

KC210158 CDMRP (Rini) 07/01/2022-06/30/2025

*RNAseq-Based Biomarkers Identify Targetable Biologic Drivers of Kidney Cancer*

Goals: This project is innovative in that for the first time we are using specific patient tumor information to guide treatment. If successful, this project will have implications for how we approach treatment not only in kidney cancer, but also more broadly for other cancers in Service Members, their families, Veterans, and the American public.

Role: Co-I

KC210138 CDMRP (Dere) 07/01/2022-06/30/2025

*Targeting a Combined VHL and 3p Chromatin Remodeler Deficit in Renal Cell Carcinoma*

Goals: Dr. Rathmell and her team will be primarily responsible for the generating the patient derived organoid models which will be treated with inhibitors of hits identified from the CRISPR-Cas9 screen and the AURKA and PI3K/AKT inhibitors to evaluate viability described in Aim 3.

Role: Co-I

W81XWH-21-KCRP-CTA (Rini) 07/01/2022-06/30/2025

*Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)*

Goals: The purpose of this study is to test our hypothesis that a new tool that measures the genetic signature of kidney cancer tumors can precisely match a patient to a pure immunotherapy regimen or an immunotherapy/tumor blood vessel poison combination.

Role: Co-I

2P30CA068485-26 Cancer Center Support Grant (Pietenpol) 09/15/2020-08/31/2025

Major Goals: Vanderbilt cancer-related expertise and resources in order to deliver its mission of alleviating cancer death and suffering through pioneering research; innovative patient-centered care; and evidence-based prevention, education and community initiatives. This mission is accomplished through translation of exceptional cancer research into interventions for the prevention, diagnosis and treatment of cancer.

Role: Co-I

K12 CA090625-16, NIH (MPI K Rathmell/Friedman) 07/01/2011-06/30/2027

*Vanderbilt Clinical Oncology Research Career Development Program (VCORCDP)*

This award supports the career development of junior faculty cancer-focused translational researchers. \*Supplement awarded to provide additional trainee in tumor immunology.

Transitioned to PI Deb Friedman, Paula Hurley

T32 CA217834-01 (PI K Rathmell)

08/01/2018-07/31/2023

*Vanderbilt Integrated Molecular Oncology Research Training Program (VIMO-RTP)*

This award supports the career development of cancer-focused translational researchers in clinical training. Transitioned to PI Doug Johnson, Deb Friedman

Vanderbilt-Incyte Research Alliance Program Grant (Savona)

07/30/2016-12/31/2022

*Subaward-testing mechanisms of T cell response in kidney tumors*

Major Goals: The major goal of this project is to mobilize the skills, knowledge and experience developed at Vanderbilt-Ingram Cancer Center for a focused and coordinated attack on cancer with the goal of expanding understanding of cancer biology, the mechanisms of action of Incyte compounds on both solid and liquid tumors, approaches to patient selection and stratification, and new therapeutic targets in oncology.

Role: Co-I

R01CA203012 (MPI Rathmell/Walker)

07/01/2016-06/30/20

*Methyltransferase Contributions to Genomic Stability and Cancer*

This proposal is a comparison of a novel bifunctional activity of SETD2 to act as a methyltransferase for histones as well as microtubules involved in mitotic spindle formation.

R01CA198482 (MPI Rathmell/Davis/Strahl)

05/01/2015 – 04/30/2022

*Chromatin Maintenance in Cancer Progression*

This multiPI project approaches the biochemical developments associated with DNA repair defects linked to SETD2 loss in cancer.

ORIEN New Oncologic Visionary Award (NOVA) (PI Ganesan)

08/01/19-07/31/2022

*Endogenous Retroviruses in Cancer Immunotherapy*

Role: Co-I

CA160728P1 (MPI Jonasch, Rathmell, Johnson)

09/01/2017-08/31/2020

Department of Defense, Team Science Award

*Prognostic and Predictive Markers of Immunogenicity in Renal Cell Carcinoma*

This project is a Team Science investigation of tissue specific markers of immunogenicity examining archival samples at VUMC, the Tennessee Valley VA Medical Center, and MDACC.

AACR-Kure It Research Grant (PI Rathmell)

07/01/2018-06/30/2020

*Immunosuppression in the RCC tumor microenvironment*

This study examines the metabolic and exosome components of the microenvironment.

VUMC57787(U27DD001155)

09/30/2015-09/29/2016

ATHN/Centers for Disease Control

*Community Counts: Public Health Surveillance for Bleeding Disorders*

Subrecipient of the Cooperative Agreement with CDC and American Thrombosis and Hemostasis Network (ATHN) public health surveillance of patients with bleeding and clotting disorders

VUMC40097(H30MC24046) (Rathmell)

06/01/2012-05/31/2016

Health Resources and Services Administration

Comprehensive Hemophilia Diagnostic and Treatment Center from Health Resources and Services Administration This Agreement provides support funds for the Southeast Region's MCHB Bleeding Disorders Program.

VUMC04965(U27DD000862) (Rathmell)

09/30/2011-09/29/2016

Centers for Disease Control and Prevention

Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders Subrecipient of the Cooperative Agreement with CDC and American Thrombosis and Hemostasis Network (ATHN) for public health surveillance of patients with bleeding and clotting disorders.

K24CA172355-01A1(PI Rathmell)

07/01/2013 – 06/30/2018

*Prospective Studies for Clinical Translation.*

This proposal will support my continued efforts to mentor translational junior physician scientists in careers bridging clinical trials with genomic medicine.

R21CA184387-01 (PI Rathmell)

04/01/2015 – 03/31/2017 (NCE)

*Exploiting DLL4 inhibition as a mechanism to overcome resistance in ccRCC*

This collaborative study with Vicki Bautch and Paul Dayton explores an innovative strategy to assess and overcome resistance to VEGFR TKI therapy in renal cell carcinoma.

Not Assigned, Forbeck Foundation (PI Rathmell)

08/01/2015-07/31/2017

*Immune Cell Genomic and Metabolomic Profiling in RCC*

Project examines the clonality of B and T cell subsets in RCC tumors.

UCRF INNOVATOR Award (PI Rathmell) \$50,000

08/01/13 – 07/30/2015

UNC Lineberger (UCRF)

*Examining DLL4 Inhibition in Renal Cell Carcinoma*

Assess Notch pathway targeted therapy in renal cell carcinoma.

V Foundation (PI Rathmell/Lieb/Davis) \$600,000 (over 3 years)

11/01/2012 – 12/31/2015

*Reprogramming the Histone Code in Renal Cell Carcinoma*

This proposal develops a biochemical, genomic, and therapeutic approaches to reveal the impact of epigenetic reprogramming in kidney cancer, and develop strategies to reverse these changes.

Cancer Research Institute (PI J. Rathmell)\$200,000

07/01/2013 – 06/30/2016

*Metabolic Immunosuppression of T cells in Clear Cell Renal Cell Carcinoma and anti-PD-1 Therapy*

This study examines the competition between tumor cells and resident tumor lymphocytes for nutrients and responsiveness of tumor lymphocytes to immune stimulation.

American Cancer Society (PI Rathmell) \$798,884 06/01/2010 – 05/31/2014

*Ror2 Signaling in Renal Cell Carcinoma*

This proposal describes a project to elucidate the transcriptional regulation, functional signaling properties, and implications for human cancer of Ror2 kinase expression.

LCCC1219 (PI Rathmell/Chang) \$45,000 01/01/2013 – 12/31/2014

NC TRaCS

*Contract Enhanced Ultrasound to Detect Early Renal Cell Carcinomas*

This study will pilot the use of CEU (contrast enhanced ultrasound) as a risk stratification tool for patients at high risk for renal cell carcinoma.

LCCC1213 (PI Rathmell) \$30,000 07/01/2012 – 06/30/2014

UNC-Siemens Partnership

*Defining Molecular and Functional Imaging Correlates of RCC Biological Features*

This project will use MR-PET imaging to create a three dimensional map of tumor heterogeneous features, for molecular correlation with laboratory based biomarkers.

1-R01-CA121781 (PI Rathmell) \$190,000 (per yr, 5 years) 07/01/2007 – 06/30/20

*Genetic Events in the Development of Renal Cell Carcinoma*

Not Assigned (PI Rathmell) \$700,000 (over 2 years) 10/15/2011 – 10/14/2013

NCI Experimental Therapeutics (NExT) Program

*Targeting Ror2 for Therapeutic Benefit*

CALGB (PI Rathmell) \$88,000 08/01/2010 – 07/31/2012

Cancer and Leukemia Group B

*Molecular Stratification of Renal Cell Carcinoma to Predict Response to Treatment*

AACR (PI Rathmell) 07/01/2010 – 06/30/2012

AACR Landon Foundation INNOVATOR Award for Personalized Medicine

Molecular Stratification of RCC for Improved Prognosis

Bayer (PI Rathmell) \$150,000 08/01/2007 – 08/31/2009

*A Pilot Neoadjuvant Study of Sorafenib Treatment for Stage II or Greater Renal Cell Carcinoma*

This support funds a clinical trial effort to use develop multimodality therapy for renal cell carcinoma.

NCTCS (PI Janzen/Rathmell) \$50,000 07/01/2009 – 06/30/2010

North Carolina Translational and Clinical Sciences

*Ror2: Bench to bedside*

This pilot project supports partial funding for a technician and graduate student to work on aspects of the Ror2 project generating preliminary data to develop Ror2 as a target for kinase inhibitor development.

LCCC (PI Rathmell/Cowey) \$40,000 06/01/2008 – 05/30/2009  
 Lineberger Cancer Center  
*Metabolic Effects of HIF Expression on Renal Cell Carcinoma*  
 This proposal aims to evaluate the effects of HIF-1 vs HIF-2 on measures of metabolic activity in vitro, in vivo, and in patients as a potential indicator of response to targeted therapy.

DDCF (PI Rathmell) \$125,000 08/1/2006 – 07/31/2009  
 Doris Duke Charitable Foundation  
*Renal Cell Carcinoma: Biologic Indicators of Response to Targeted Therapy*  
 The objectives in this research are to 1) identify genetic and molecular characteristics of renal cell carcinoma critical to the invasive potential of this disease, and 2) determine reproducible biomarkers or indicators of renal cell carcinoma response to therapy.

ACS RSG (PI Rathmell) \$164,693 07/01/2006 – 06/30/2007  
 American Cancer Society  
*Genetic Events in Renal Cell Carcinoma*  
 This proposal was relinquished after one year due to overlap with the R01.

VHLFA (PI Rathmell) \$35,000 07/01/2005 – 06/30/2006  
 VHL Family Alliance  
*Models of VHL Disease*  
 This study proposed a novel strategy to engage somatic events in renal cells to mimic the development of RCC.

PI Rathmell \$30,000 06/01/2005 – 05/30/2006  
 UNC School of Medicine  
*Building a Translational Program in Renal Cell Carcinoma*  
 This support funded a clinical and translational effort to develop a close interface between molecular science and the clinical trials program.

PI Rathmell/Turner \$35,000 06/01/2004 – 05/30/2005  
 Lineberger Cancer Center  
*Cox-2 Expression in Renal Cell Carcinoma*  
 An investigation of Cox-2 as a HIF target gene and potential therapeutic target in renal cell carcinoma.

K08 CA098410 (PI Rathmell) \$105,000 (yearly, 5 years) 07/01/2003 – 06/30/2008  
*Functional and Tissue Specific Effects of VHL Mutation in Renal Cell Carcinoma*  
 This project launched our analysis of VHL disease associated mutations in in vitro and in vivo studies.

V Foundation (PI Rathmell)                      \$100,000                      08/01/2003 – 07/31/2005  
*VHL Mutations in Renal Cell Carcinoma*  
A comparative analysis of structurally distinct VHL mutations and how these distinctions participate in the development of renal cell carcinoma.

**Publications and Presentations:**

Original Research (peer reviewed)

1. Wiens, DJ, Mann, TK, Fedderson, DE, **Rathmell, WK**, and Franck, BH Early heart development in the chick embryo: effects of isotretinoin on cell proliferation, alpha-actin synthesis, and development of contractions. *Differentiation*, 51: 105-112, 1992. PMID: 1473624
2. **Rathmell, WK** and Chu, G. Involvement of the Ku autoantigen in the cellular response to DNA double-strand breaks. *Proc Natl Acad Sci U S A*, 91: 7623-7627, 1994. PMID: 8052631
3. **Rathmell, WK** and Chu, G. A DNA end-binding factor involved in double-strand break repair and V(D)J recombination. *Mol Cell Biol*, 14: 4741-4748, 1994. PMID: 7516471
4. Smider, VV\*, **Rathmell, WK\***, Lieber, MR, and Chu, G. Restoration of X-ray resistance and V(D)J recombination in mutant cells by Ku cDNA. *Science*, 266: 288-291, 1994. PMID: 7939667 \*Co-first authorship.
5. Errami, A, Smider, VV, **Rathmell, WK**, He, DM, Hendrickson, EA, Zdzienicka, MZ, and Chu, G. Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants. *Mol Cell Biol*, 16: 1519-1526, 1996. PMID: 8657125
6. **Rathmell, WK**, Kaufmann, WK, Hurt, JC, Byrd, LL, and Chu, G. DNA-dependent protein kinase is not required for accumulation of p53 or cell cycle arrest after DNA damage. *Cancer Res*, 57: 68-74, 1997. PMID: 8988043
7. Smider, VV, **Rathmell, WK**, Brown, G, Lewis, S, and Chu, G. Failure of hairpin-ended and nicked DNA to activate DNA-dependent protein kinase: implications for V(D)J recombination. *Mol Cell Biol*, 18: 6853-6858, 1998. PMID: 9774698
8. **Rathmell, WK**, Arguin, P, Chan, S, and Yu, A. Yersinia pseudotuberculosis bacteremia and splenic abscess in a patient with non-insulin-dependent diabetes mellitus. *West J Med*, 170: 110-112, 1999. PMID: 10063398
9. Mack, FA, **Rathmell, WK**, Arsham, AM, Gnarra, J, Keith, B, and Simon, MC. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. *Cancer Cell*, 3: 75-88, 2003. PMID: 12559177
10. **Rathmell, WK**, Acs, G, Simon, MC, and Vaughn, DJ. HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma. *Anticancer Res*, 24: 167-169, 2004. PMID: 15015593
11. **Rathmell, WK**, Hickey, MM, Bezman, NA, Chmielecki, CA, Carraway, NC, and Simon, MC. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. *Cancer Res*, 64: 8595-8603, 2004. PMID: 15574766

12. **Rathmell, WK**, Malkowicz, SB, Holroyde, C, Luginbuhl, W, and Vaughn, DJ. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer. *Am J Clin Oncol*, 27: 109-112, 2004. PMID: 15057147
13. Gollob, JA, **Rathmell, WK**, Richmond, TM, Marino, CB, Miller, EK, Grigson, G, Watkins, C, Gu, L, Peterson, BL, and Wright, JJ. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. *J Clin Oncol*, 25: 3288-3295, 2007. PMID: 17664476
14. Hickey, MM, Lam, JC, Bezman, NA, **Rathmell, WK**, and Simon, MC. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. *J Clin Invest*, 117: 3879-3889, 2007. PMID: 17992257
15. Amin, C, Wallen, E, Pruthi, RS, Calvo, BF, Godley, PA, and **Rathmell, WK**. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. *Urology*, 72: 864-868, 2008. PMID: 18684493
16. Gordan, JD, Lal, P, Dondeti, VR, Letrero, R, Parekh, KN, Oquendo, CE, Greenberg, RA, Flaherty, KT, **Rathmell, WK**, Keith, B, Simon, MC, and Nathanson, KL. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. *Cancer Cell*, 14: 435-446, 2008. PMID: 19061835; PMC2621440
17. Hacker, KE, Lee, CM, and **Rathmell, WK**. VHL type 2B mutations retain VBC complex form and function. *PLoS One*, 3: e3801, 2008. PMID: 19030229; PMC2583047
18. **Rathmell, WK** and Monk, JP. High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review. *Urology*, 72: 659-663, 2008. PMID: 18649931
19. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet*, 372(9637):449-56, 2008. PMID:18653228. \*Indexed as **K. Rathmell**.
20. Lee, CM, Hickey, MM, Sanford, CA, McGuire, CG, Cowey, CL, Simon, MC, and **Rathmell, WK**. VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. *Oncogene*, 2009, 28: 1694-1705. PMID: 19252526; PMC2667565
21. Wright, TM, Brannon, AR, Gordan, JD, Mikels, AJ, Mitchell, C, Chen, S, Espinosa, I, van de Rijn, M, Pruthi, RS, Wallen, E, Edwards, L, Nusse, R, and **Rathmell, WK**. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. *Oncogene*, 28: 2513-2523, 2009. PMID: 19448672; PMC2771692
22. Kurpad, R, Kim, WY, **Rathmell, WK**, Godley, P, Whang, Y, Fielding, J, Smith, L, Pettiford, A, Schultz, H, Nielsen, ME, Wallen, EM, Pruthi, RS. A multidisciplinary approach to the management of urologic malignancies: Does it influence diagnostic and treatment decisions? *Urol. Oncol*, 29(4):378-82, 2011. PMID: 19576797
23. Cowey, CL, Fielding, J, and **Rathmell, WK**. The Loss of Radiographic Enhancement in Primary Renal Cell Carcinoma Tumors Following Multi-targeted Receptor Tyrosine Kinase Therapy is an Additional Indicator of Response. *Urology*, 75(5):1108-13.e1, 2010. PMID: 19931124

24. Kim WY, Whang YE, Pruthi RS, Baggstrom MQ, **Rathmell WK**, Rosenman JG, Wallen EM, Goyal LK, Grigson G, Watkins C, Godley PA. Neoadjuvant docetaxel/ estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial. *Urol. Oncol*, 29(6):608-13, 2011. PMID: 20022268
25. Pruthi, RS, Nielsen, M, Heathcote, S, Wallen, EM, **Rathmell, WK**, Godley, P, Whang, Y, Fielding, J, Schultz, H, Grigson, G, Smith, A, Kim, WY. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. *BJU Int*, 106(3):349-56, 2010. 20089114
26. Cowey, CL, Amin, C, Pruthi, RS, Wallen, EM, Nielsen, ME, Grigson, G, Watkins, C, Nance, KV, Crane, J, Jalkut, M, Kim, WY, Godley, PA, Whang, YE, Fielding, JR, and **Rathmell, WK**. A Neoadjuvant Clinical Trial with Sorafenib for Patients with Stage II or Greater Renal Cell Carcinoma. *J. Clin. Oncol.*, 28(9): 1502-7, 2010. PMID: 20159822
27. Wright, TM, **Rathmell, WK**. Identification of Ror2 as a hypoxia inducible factor (HIF) target in von Hippel-Lindau (VHL)-associated renal cell carcinoma. *J Biol Chemistry*. 285(17):12916-24, 2010. PMID: 20185829; PMC2857057
28. Chen, S, Sanford, CA, Sun, J, Choi, V, Van Dyke, T, Samulski, RJ, and **Rathmell, WK**. VHL and PTEN loss coordinate to promote liver vascular lesions. *Angiogenesis*, 13(1): 59-69, 2010. PMID: 20221685
29. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A; RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. *Cancer*. 116(18):4256-65, 2010. PMID: 20549832. \* Indexed as **K. Rathmell**.
30. Liu, H, Brannon, AR, Reddy, A, Alexe, G, Seiler, M, Arreola, A, Oza, J, Yao, M, Juan, D, Liou, L, Ganesan, S, Levine, AJ, **Rathmell, WK\***, Bhanot, G\*, Identifying direct mRNA targets of microRNA in clear cell renal cell carcinoma. *BMC Systems Biology*, 4(1):51, 2010. \*Co-corresponding authors. PMID: 20420713; PMC2876063
31. Bender, AA, Tang, W, Middeldorp, JM, Greijer, AE, Thorne, LB, Funkhouser, WK, **Rathmell, WK**, Gulley, MA Epstein-Barr Virus Latent Membrane Protein 1 is not Associated with Vessel Density nor with Hypoxia Inducible Factor 1 Alpha Expression in Nasopharyngeal Carcinoma Tissue. *Head and Neck Pathology*. 3(4):276-82. 2010. PMID: 20871783
32. Brannon, AR \*, Reddy, A.\*, Seiler, M., Arreola, A., Moore, D.T., Pruthi, R., Wallen, E., Liu, H., Ljungberg, B, Zhao, H, Brooks, JD, Ganesan, S, Bhanot, G, and **Rathmell, WK**. Molecular Stratification of Clear Cell Renal Cell Carcinoma Reveals Distinct Subtypes and Survival Patterns. \*Co-first authorship. *Genes and Cancer*, 1(2): 152-163, 2010. PMID: 20871783; PMC2943630
33. Whang YE, Armstrong AJ, **Rathmell WK**, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. *Urol Oncol*. 31(1):82-6, 2013. PMID: 21470103
34. Teng BL, Hacker KE, Chen S, Means AR, **Rathmell WK**. Tumor Suppressive Activity of Prolyl Isomerase Pin1 in Renal Cell Carcinoma. *Mol Oncol*, Oct; 5(5):465-74, 2011. PMID: 21764651; PMC3194764 \*Cover.

35. Manvar AM, **Rathmell WK**, Ferguson J, Pruthi RS, Nielsen ME, Wallen EM, Nolan N, Raynor MC. Carcinoma in a Cadaveric Transplant Kidney. *Urology*, 61(2):258-68, 2012. PMID: 22014593
36. Brannon, AR, Haake, SM, Hacker, KE, Pruthi, RS, Wallen, EM, Nielsen, ME, and **Rathmell, WK**. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. *Eur Urol*. 2012 Feb;61(2):258-68. PMID: 22030119; PMC3244546
37. Gamper, AM, Qiao, X, Kim, J, Zhang, L, DeSimone, MC, **Rathmell, WK**, Wan, Y. Regulation of KLF4 turnover reveals an unexpected tissue specific role of pVHL in tumorigenesis. *Molecular Cell*, 45(2):233-43, 2012. PMID: 22284679. PMC3982234
38. Khandani, A, Cowey, CL, Moore, DT, Gohil, H, **Rathmell, WK**. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. *Nuclear Medicine Communication*, 33(9):967-73, 2012. PMID: 22714005
39. Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, Wallen EM, Crane JM, Kim WY, **Rathmell WK**, Godley PA, Whang YE Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. *BJU Int*. 2012 110(11 Pt B):E721-6. PMID: 23016517
40. Stein A, Bellmunt J, Escudier B, Kim D, Stergiopoulos SG, Mietlowski W, Motzer RJ; RECORD-1 Trial Study Group. Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial. *Eur Urol*. 2013 Dec;64(6):994-1002. PMID: 23219086. Indexed as **K. Rathmell**.
41. Valgus J, Singer EA, Berry S, **Rathmell WK**. Ethical Challenges: Managing Oncology Drug Shortages. *J Oncol Pract*, 9(2):e21-3, 2013. PMCID: PMC3595447
42. Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, **Rathmell WK**, Xie XJ, Brugarolas J. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. *Lancet Oncol*, 14(2):159-167, 2013. PMID: 23333114
43. Gallagher SA, Smith AB, Matthews JE, Potter CW, Woods ME, Raynor M, Wallen EM, **Kimryn Rathmell W**, Whang YE, Kim WY, Godley PA, Chen RC, Wang A, You C, Barocas DA, Pruthi RS, Nielsen ME, Milowsky MI. Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database-UNC GOLD. *Urol Oncol*. 2014 Jan;32(1):32.e1-9 PMID: 23434424 \*Indexed as Kimryn Rathmell, W.
44. Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, **Rathmell WK**, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. *Cell Metabolism*. 17(3):372-85, 2013. PMCID: PMC4003458
45. Lockhart AC, Brose MS, Kim ES, Johnson DH, Peppercorn JM, Michels DL, Storm CD, Schuchter LM, **Rathmell WK**. Physician and Stakeholder Perceptions of Conflict of Interest (COI) Policies in Oncology. *J Clin Oncol*, 31(13):1677-82, 2013. PMID: 23530092
46. Chen, J, Appelbaum, D, Kocherginsky, M, Cowey, CL, **Rathmell, WK**, McDermott, D, Stadler, W. FDG-PET as a Predictive Biomarker for Therapy with Everolimus in

- Metastatic Renal Cell Cancer (mRCC). *Cancer Med.* 2013 Aug;2(4):545-52. PMCID: PMC3799289
47. Olshan, AF, Kuo, T, Meyer, A-M, Nielsen, ME, Purdue, MP, and **Rathmell, WK**. Racial Difference in Histologic Subtype of Renal Cell Carcinoma. *Cancer Med.* 2013 Oct;2(5):744-9. PMCID: PMC3892806
  48. **The Cancer Genome Atlas Network**. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature*, 499(7456):43-9, 2013. PMID:23792563. \*\*Analysis Working Group, Transcriptional Analysis Lead, Clinical Data Lead, Lead Writing Team.
  49. DeSimone, M, **Rathmell, WK\***, Threadgill, D\*, Pleiotropic Effects of the Trichloroethylene-Associated P81S VHL Mutation on Metabolism, Apoptosis and ATM-Mediated DNA Damage Response. *J. Natl. Cancer Inst*, 105(18):1355-64, 2013. PMCID: PMC3776265. Co-corresponding authors.
  50. Rasmussen, N, Wright, T, Debebe, Z, Hacker, KE, Sen, O, Major, MB, Green, J., Wahl, G, **Rathmell, WK**. Ror2 creates a poised signal for Wnt signaling in renal cell carcinoma. *J Biol Chemistry*, 288(36):26301-10, 2013. PMCID: PMC3764835
  51. **Cancer Genome Atlas Research Network**. Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature*. 2014 507(7492):315-22. PMID: 24476821. \*Collaborator, major contributor to analysis, Indexed as Kimryn Rathmell
  52. Simon, J\*, Hacker, KE\*, Brannon, AR, Parker, JS, Weiser, M, Ho, TH, Kuan PF, Jonasch E, Furey TS, Prins JF, Lieb, JD\*\*, **Rathmell, WK\*\***, Davis, IJ.\*\* Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. *Genome Research*. 2014 24(2):241-50. PMCID: PMC3912414
  53. Jaggi R, Spence R, **Rathmell WK**, Bradbury A, Peppercorn J, Grubbs S, Moy B. Ethical considerations for the clinical oncologist in an era of oncology drug shortages. *Oncologist*. 2014;19(2):186-92. PMCID: PMC3926786
  54. Arreola, A, Cowey, CL, Coloff, J, Rathmell, JC, and **Rathmell, WK**. HIF1 and HIF2 exert differential preferences on nutrient utilization. *PLoS One*. 9(5):e98705. PMC4039535
  55. Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, **Rathmell, WK**. ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma. *Eur Urol*. 2014 66(1):77-84 PMC4058355
  56. Khandani AH, **Rathmell, WK**, Wallen EM, Ivanovic M. PET/CT with (124)I-cG250: great potential and some open questions. *AJR Am J Roentgenol*. 2014 Aug;203(2):261-2. PMID: 25055257
  57. Davis, CF\*, Ricketts, C\*, Wang, M\*, Yang, L\*, Cherniack, AD, Shen, H, Buhay, C, Kim, SC, Fahey, CC, Hacker, KE, Bhanot, G, Gordenin, DA, Chu, A, Gunaratne, PH, Biehl, M, Seth, S, Kaipparettu, BA, Bristow, CA, Donehower, LA, Wallen, EM, Smith, AB, Tickoo, SK, Tamboli, P, Reuter, V, Schmidt, LS, Hsieh, JJ, Choueiri, TK, Hakimi, AA, The Cancer Genome Atlas Research Network\*\*, Chin, L, Meyerson, ML, Kucherlapati, R, Park, W-Y, Robertson, AG, Laird, PW, Henske, EP, Kwiatkowski, DJ, Park, PJ, Morgan, M, Shuch, B, Muzny, D, Wheeler, DA, Linehan, WM, Gibbs, RA, **Rathmell, WK\*\***, Creighton, CJ\*\*. The somatic genomic landscape of chromophobe renal cell carcinoma. *Cancer Cell*. 2014 26(3):319-330. PMCID PMC4160352. \*Authors contributed equally to the work.

\*\*Project Leader, Transcript Analysis Team Leader, Co-corresponding author. Selected for cover.

58. Begg CB, Seshan VE, Zabor EC, Furberg H, Arora A, Shen R, Maranchie JK, Nielsen ME, **Rathmell WK**, Signoretti S, Tamboli P, Karam JA, Choueiri TK, Hakimi AA, Hsieh JJ. Genomic investigation of etiologic heterogeneity: methodologic challenges. *BMC Med Res Methodol*. 2014 Dec 22;14(1):138. PMID: 25532962
59. Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Wallen EM, Simpson C, Norris JL, Janzen WP, **Rathmell WK**. Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. *PLoS One*. 2014 Dec 26;9(12):e116101. PMID: 25542006.
60. Sendor AB, Hacker KE, Chen S, Corona AL, Sen O, Chiang DY, Snaveley A, Rogers AB, Montgomery SA, **Rathmell WK**, McRee AJ. Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss. *Gastrointest Cancer*. 2015 Feb 1;5:61-71. PMCID: PMC4383253
61. Rose TL, Deal AM, Basch E, Godley PA, **Rathmell WK**, Kim WY, Whang YE, Dunn MW, Wang A, Chen RC, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, Smith AB, Milowsky MI. Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. *Urol Oncol*. 2015 33(9):38 PMID: 26122712
62. Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, **Rathmell WK**, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukheim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Chevillat JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J,

- Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R; Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N Engl J Med*. 2015 374(2):135-45 PMID: 26536169. \*\*Analysis Working Group, Transcript Analysis Leader.
63. Haake SM, Brooks SA, Welsh E, Fulp WJ, Chen DT, Dhillon J, Haura E, Sexton W, Spiess PE, Pow-Sang J, **Rathmell WK**, Fishman M. Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities. *Urol Oncol*. 2016 Mar;34(3):122. PMID: 26546482 PMCID: PMC4761468
64. Brooks SA, Khandani A, Fielding J, Lin W, Sills T, Lee Y, Arreola A, Milowsky MI, Wallen EM, Woods ME, Smith AB, Nielsen ME, Parker JS, Lalush DS, **Rathmell WK**. Alternate metabolic programs define regional variation of relevant biological features in renal cell carcinoma progression. *Clin Cancer Res*. 2016 Jun 15;22(12):2950-9. PMID: 26787754
65. Kishon RJ, Barnes CE, Nichols AG, Cohen S, Gerriets VA, Siska PJ, Macintyre AN, Goraksha-Hicks P, de Cubas AA, Liu T, Warmoes MO, Abel ED, Yeoh AE, Gershon TR, **Rathmell WK**, Richards KL, Locasale JW, Rathmell JC. AMPK Is Essential to Balance Glycolysis and Mitochondrial Metabolism to Control T-ALL Cell Stress and Survival. *Cell Metab*. 2016 Apr 12;23(4):649-62. PMID: 27076078, PMCID: PMC4832577
66. Haake SM, Li J, Bai Y, Kinose F, Fang B, Welsh EA, Zent R, Dhillon J, Pow-Sang JM, Chen YA, Koomen JM, **Rathmell WK**, Fishman M, Haura EB. Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. *Clin Cancer Res*. 2016 22(22):5605-5616. PMID: 27220961
67. Park IY, Powell RT, Tripathi DN, Dere R, Ho TH, Blasius TL, Chiang YC, Davis IJ, Fahey CC, Hacker KE, Verhey KJ, Bedford MT, Jonasch E, **Rathmell WK**, Walker CL. Dual Chromatin and Cytoskeletal Remodeling by SETD2. *Cell*. 2016 Aug 11;166(4):950-62. PMID: 27518565
68. Hacker KE, Fahey CC, Shinsky SA, Chiang YJ, DiFiore JV, Jha DK, Vo AH, Shavit JA, Davis IJ, Strahl BD, **Rathmell WK**. Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation. *J Biol Chem*. 2016 Sep 30;291(40):21283-21295. PMID: 27528607
69. de Velasco G, Miao D, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, **Rathmell WK**, Van Allen EM, Choueiri TK. Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. *Cancer Immunol Res*. 2016 Oct;4(10):820-822. PMID: 27538576
70. Park IY, Chowdhury P, Tripathi DN, Powell RT, Dere R, Terzo EA, **Rathmell WK**, Walker CL. Methylated  $\alpha$ -tubulin antibodies recognize a new microtubule modification on mitotic microtubules. *MAbs*. 2016 Nov/Dec;8(8):1590-1597. PMID: 27594515
71. Beckermann KE, Jolly PC, Kim JY, Bordeaux J, Puzanov I, **Rathmell WK**, Johnson DB. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. *J Immunother Cancer*. 2017 Jan 17;5:1. doi: 10.1186/s40425-016-0206-1. eCollection 2017. PMID: 28105368

72. Kasoji SK, Chang EH, Mullin LB, Chong WK, **Rathmell WK**, Dayton PA. A Pilot Clinical Study in Characterization of Malignant Renal Cell Carcinoma Subtype with Contrast-Enhanced Ultrasound. *Ultrason Imaging*. 2017 Mar;39(2):126-136. PMID: 27659687
73. Murakami A, Wang L, Kalhorn S, Schraml P, **Rathmell WK**, Tan AC, Nemenoff R, Stenmark K, Jiang BH, Reyland ME, Heasley L, Hu CJ. Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. *Oncogenesis*. 2017 Jan 16;6(1):e287. PMID: 28092369
74. Nakajima, E, Leger, P, Mauer, IA, Neuss, MN, Chism, DD, **Rathmell, WK**. A case report of severe type B lactic acidosis following first dose of nivolumab in a VHL-mutated metastatic renal cell carcinoma. *Kidney Cancer*. 2017 1(1)
75. Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, Lichtenberg TM, Murray BA, Ghayee HK, Else T, Ling S, Jefferys SR, de Cubas AA, Wenz B, Korpershoek E, Amelio AL, Makowski L, **Rathmell WK**, Gimenez-Roqueplo AP, Giordano TJ, Asa SL, Tischler AS; Cancer Genome Atlas Research Network, Pacak K, Nathanson KL, Wilkerson MD. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. *Cancer Cell*. 2017 Feb 13;31(2):181-193. PMID: 28162975 (Analysis working group)
76. Yin Q, Hung SC, Wang L, Lin W, Fielding JR, **Rathmell WK**, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D.: Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study. *Sci Rep*. 2017 Mar 3;7:43356. PMID: 28256615
77. Siska PJ, Johnpulle RAN, Zhou A, Bordeaux J, Kim JY, Dabbas B, Dakappagari N, Rathmell JC, **Rathmell WK**, Morgans AK, Balko JM, Johnson DB.: Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. *Oncoimmunology*. 2017 Mar 20;6(4) PMID: 28507813
78. Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, Chiang YJ, Corona AL, Gemta LF, Vincent BG, Wang RC, Kim B, Hong J, Chen CL, Bullock TN, Irish JM, **Rathmell WK\***, Rathmell JC\*. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. *JCI Insight*. 2017 Jun 15;2(12). [Epub ahead of print] PMID: 28614802 \*Co-corresponding author.
79. Chang EH, Chong WK, Kasoji SK, Fielding JR, Altun E, Mullin LB, Kim JI, Fine JP, Dayton PA, **Rathmell WK**. Diagnostic accuracy of contrast-enhanced ultrasound for characterization of kidney lesions in patients with and without chronic kidney disease. *BMC Nephrol*. 2017 Aug 9;18(1):266. PMID: 28793871
80. Sun M, Tong P, Kong W, Dong B, Huang Y, Park IY, Zhou L, Liu XD, Ding Z, Zhang X, Bai S, German P, Powell R, Wang Q, Tong X, Tannir NM, Matin SF, **Rathmell WK**, Fuller GN, McCutcheon IE, Walker CL, Wang J, Jonasch E. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. *Cancer Res*. 2017 Oct 1;77(19):5313-5326. Epub 2017 Aug 14. PMID: 28807937
81. Rojas JD, Lin F, Chiang YC, Chytil A, Chong DC, Bautch VL, **Rathmell WK**, Dayton PA.

- Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy. *Theranostics*. 2018 Jan 1;8(1):141-155. PMID:29290798
82. Dronamraju R, Jha DK, Eser U, Adams AT, Dominguez D, Choudhury R, Chiang YC, **Rathmell WK**, Emanuele MJ, Churchman LS, Strahl BD. Set2 methyltransferase facilitates cell cycle progression by maintaining transcriptional fidelity. *Nucleic Acids Res*. 2018 Feb 16;46(3):1331-1344. PMID: 29294086
  83. Arreola A, Payne LB, Julian MH, de Cubas AA, Daniels AB, Taylor S, Zhao H, Darden J, Bautch VL, **Rathmell WK\***, Chappell JC\*. Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch. *JCI Insight*. 2018 Feb 22;3(4):e92193. PMID:29467323. \*Co-corresponding author.
  84. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhi R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Lui W, Merino MJ, Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network, Spellman PT\*, **Rathmell WK\***, Linehan WM\*. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Rep*. 2018 Apr 3;23(1):313-326.e5. Erratum in: *Cell Rep*. 2018 Jun 19;23(12):3698. PMID: 29617669 \*Co-corresponding, Project co-leader.
  85. Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, **Rathmell WK**, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI. Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. *J Clin Oncol*. 2018 Jun 1;36(16):1588-1593. PMID: 29641297
  86. Kuwahara Y, Kennedy LM, Karnezis AN, Mora-Blanco EL, Rogers AB, Fletcher CD, Huntsman DG, Roberts CWM, **Rathmell WK**, Weissman BE. High Frequency of Ovarian Cyst Development in *Vhl2B/+;Snf5+/-* Mice. *Am J Pathol*. 2018 Apr 22. 9440(17)31178-1. PMID: 29684361
  87. Chiang YC, Park IY, Terzo EA, Tripathi DN, Mason FM, Fahey CC, Karki M, Shuster CB, Sohn BH, Chowdhury P, Powell RT, Ohi R, Tsai YS, de Cubas AA, Khan A, Davis IJ, Strahl BD, Parker JS, Dere R, Walker CL, **Rathmell WK**. SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma. *Cancer Res*. 2018 Jun 15;78(12):3135-3146. PMID: 29724720
  88. Yin Q, Hung SC, **Rathmell WK**, Shen L, Wang L, Lin W, Fielding JR, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D. Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma. *Clin Radiol*. 2018 9260(18)30168-5. PMID:29801658
  89. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, **Rathmell WK**, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenewald V, Choueiri TK, Nickles D, Jhunjunwala S, Piau-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Clinical activity and molecular correlates of response to atezolizumab

- alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat Med*. 2018 Jun;24(6):749-757. PMID: 29867230
90. Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, Lawrence C, Fan J, Geng J, Liu X, Hu L, Wang J, Liao C, Hong K, Zurlo G, Parker JS, Auman JT, Perou CM, **Rathmell WK**, Kim WY, Kirschner MW, Kaelin WG Jr, Baldwin AS, Zhang Q. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. *Science*. 2018 Jul 20;361(6399):290-295. PMID: 30026228
  91. Rojas, JD, Papadopoulou, V, Czernuszewicz, TJ, Rajamahendiran, RM, Chytil, A, Chiang, Y-C, Chong, DC, Bautch, VL, **Rathmell, WK**, Aylward, S, Gessner, RC, Dayton, PA. Ultrasound measurement of vascular density to evaluate response to anti-angiogenic therapy in renal cell carcinoma. *IEEE Transactions in Biomedical Engineering*. In press.
  92. Panda A, de Cubas AA, Stein M, Riedlinger G, Kra J, Mayer T, Smith CC, Vincent BG, Serody JS, Beckermann KE, Ganesan S, Bhanot G, **Rathmell WK**. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. *JCI Insight*. 2018 Aug 23;3(16):e121522. PMID: 30135306
  93. Smith CC, Beckermann KE, Bortone DS, de Cubas AA, Bixby LM, Lee SJ, Panda A, Ganesan S, Bhanot G, Wallen EM, Milowsky MI, Kim WY, **Rathmell WK**, Swanstrom R, Parker JS, Serody JS, Selitsky SR, Vincent BG. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. *J Clin Invest*. 2018 Nov 1;128(11):4804-4820. PMID: 30137025
  94. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, **Rathmell WK**, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. *JAMA Oncol*. 2018 Dec 1;4(12):1721-1728. PMID: 30242316
  95. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, **Rathmell WK**, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjunwala S, Piau-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T. Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat Med*. 2018 Oct 5. [epub ahead of print] PMID: 30291359  
 Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. *Nat Med*. 2018 Jun;24(6):749-757. PMID: 30291359
  96. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, **Rathmell WK**, Tannir NM. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients with Renal Medullary Carcinoma. *Clin Genitourin Cancer*. 2019 Feb;17(1):1-6. PMID: 30287223

97. Johnson MO, Wolf MM, Madden MZ, Andrejeva G, Sugiura A, Contreras DC, Maseda D, Liberti MV, Paz K, Kishton RJ, Johnson ME, de Cubas AA, Wu P, Li G, Zhang Y, Newcomb DC, Wells AD, Restifo NP, **Rathmell WK**, Locasale JW, Davila ML, Blazar BR, Rathmell JC. Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. *Cell*. 2018 Dec 13;175(7):1780-1795.e19. PMID: 30392958. PMCID: PMC6361668
98. Terzo EA, Lim AR, Chytil A, Chiang YC, Farmer L, Gessner KH, Walker CL, Jansen VM, **Rathmell WK**. SETD2 loss sensitizes cells to PI3K $\beta$  and AKT inhibition. *Oncotarget*. 2019 Jan 18;10(6):647-659. PMID: 30774762. PMCID: PMC6363018. Correction: *Oncotarget*. 2019 Oct 29;10(59):6391-6392.
99. Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, **Rathmell WK**, Garcia JA, Rini BI. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. *Lancet Oncol*. 2019 Aug 16. 2019 Oct;20(10):1386-1394. PMID: 31427205
100. **Rathmell, WK**, Brown, NJ, Kilburg, RR. Transformation to academic leadership: The role of mentorship and executive coaching. *Consulting Psychology Journal: Practice and Research*, 2019, 71(3), 141-160. PMID: 31787830.
101. Raddatz MA, Huffstater T, Bersi MR, Reinfeld BI, Madden MZ, Booton SE, **Rathmell WK**, Rathmell JC, Lindman BR, Madhur MS, Merryman WD. Macrophages Promote Aortic Valve Cell Calcification and Alter STAT3 Splicing. *Arterioscler Thromb Vasc Biol*. 2020 Jun;40(6):e153-e165. PMID: 32295422; PMCID: PMC7285853.
102. Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, **Rathmell WK**, Jonasch E. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. *Nat Commun*. 2020 May 1;11(1):2135. PMID: 32358509 PMCID: PMC7195420
103. de Cubas AA, Dunker W, Zaninovich A, Hongo RA, Bhatia A, Panda A, Beckermann KE, Bhanot G, Ganesan S, Karijolich J, **Rathmell WK**. DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer. *JCI Insight*. 2020 Jun 4;5(11):e137569. PMID: 32493845; PMCID: PMC7308050.
104. Vilgelm AE, Bergdorf K, Wolf M, Bharti V, Shattuck-Brandt R, Blevins A, Jones C, Phifer C, Lee M, Lowe C, Hongo R, Boyd K, Netterville J, Rohde S, Idrees K, Bauer JA, Westover D, Reinfeld B, Baregamian N, Richmond A, **Rathmell WK**, Lee E, McDonald OG, Weiss VL. Fine-Needle Aspiration-Based Patient-Derived Cancer Organoids. *iScience*. 2020 Aug 21;23(8):101408. PMID: 32771978; PMCID: PMC7415927.
105. Eulitt PJ, Altun E, Sheikh A, Wong TZ, Woods ME, Rose TL, Wallen EM, Pruthi RS, Smith AB, Nielsen ME, Whang YE, Kim WY, Godley PA, Basch EM, David GU, Ramirez J, Deal AM, **Rathmell WK**, Chen RC, Bjurlin MA, Lin W, Lee JK, Milowsky MI. Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). *Clin Genitourin Cancer*. 2020 Oct;18(5):378-386.e1. PMID: 32147364.
106. Beckermann KE, Hongo R, Ye X, Young K, Carbonell K, Healey DCC, Siska PJ, Barone S, Roe CE, Smith CC, Vincent BG, Mason FM, Irish JM, **Rathmell WK**, Rathmell JC. CD28

- costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. *JCI Insight*. 2020 Aug 20;5(16):e138729. PMID: 32814710; PMCID: PMC7455120.
107. Seervai RNH, Jangid RK, Karki M, Tripathi DN, Jung SY, Kearns SE, Verhey KJ, Cianfrocco MA, Millis BA, Tyska MJ, Mason FM, **Rathmell WK**, Park IY, Dere R, Walker CL. The Huntingtin-interacting protein SETD2/HYPB is an actin lysine methyltransferase. *Sci Adv*. 2020 Oct 2;6(40):eabb7854. PMID: 33008892.
  108. Wood CG, Ferguson JE 3rd, Parker JS, Moore DT, Whisenant JG, Maygarden SJ, Wallen EM, Kim WY, Milowsky MI, Beckermann KE, Davis NB, Haake SM, Karam JA, Bortone DS, Vincent BG, Powles T, **Rathmell WK**. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. *JCI Insight*. 2020 Nov 19;5(22):e132852. PMID: 33208553; PMCID: PMC7710285.
  109. Reinfeld BI, Madden MZ, Wolf MW, Chytil A, Bader JE, Patterson AR, Sugiura A, Cohen AS, Ali A, Do BT, Muir A, Lewis CA, Hongo RA, Young KL, Brown RE, Todd VM, Huffstater T, Abraham A, O'Neil RT, Wilson MH, Xin F, Tantawy MN, Merryman WD, Johnson RW, Williams CS, Mason EF, Mason FM, Beckermann KE, Vander Heiden MG, Manning HC, Rathmell JC\*, **Rathmell WK\***. Cell Programmed Nutrient Partitioning in the Tumor Microenvironment. *Nature*. 2021 May 4. 593(7858):282-288. doi: 10.1038/s41586-021-03442-1. PMID: 33828302. PMCID: PMC8122068
  110. Obradovic A, Chowdhury N, Haake SM, Ager C, Wang V, Vlahos L, Guo XV, Aggen DH, **Rathmell WK**, Jonasch E, Johnson JE, Roth M, Beckermann KE, Rini BI, McKiernan J, Califano A, Drake CG. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. *Cell*. 2021 May 27. doi: 10.1016/j.cell.2021.04.038. PMID: 34019793
  111. Lim AR, Vincent BG, Weaver AM, **Rathmell WK**. Sunitinib and Axitinib increase secretion and glycolytic activity of small extracellular vesicles in renal cell carcinoma. *Cancer Gene Ther*. 2022 Jun;29(6):683-696. 2021 Jun 4. doi: 10.1038/s41417-021-00345-1. PMID: 34088993
  112. Kearns S, Mason FM, **Rathmell WK**, Park IY, Walker C, Verhey KJ, Cianfrocco MA. Molecular determinants for  $\alpha$ -tubulin methylation by SETD2. *J Biol Chem*. 2021 Jul . doi: 10.1016/j.jbc.2021.100898. PMID: 34157286
  113. Baechle JJ, Hanna DN, Sekhar KR, Rathmell JC, **Rathmell WK**, Baregamian N. Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment. *Surgery*. 2021 Jul 11. doi: 10.1016/j.surg.2021.04.045. PMID: 34261605
  114. Koenning M, Wang X, Karki M, Jangid RK, Kearns S, Tripathi DN, Cianfrocco M, Verhey KJ, Jung SY, Coarfa C, Ward CS, Kalish BT, Grimm SL, **Rathmell WK**, Mostany R, Dere R, Rasband MN, Walker CL, Park IY. Neuronal SETD2 activity links microtubule methylation to an anxiety-like phenotype in mice. *Brain* 2021 Sep 4. doi: 10.1093/brain/awab200. PMID: 34014281
  115. Baechle JJ, Hanna DN, Sekhar KR, Rathmell JC, **Rathmell WK**, Baregamian N. Integrative computational immunogenomic profiling of cortisol-secreting adrenocortical carcinoma. *J Cell Mol Med*. 2021 Nov;25(21):10061-10072. doi: 10.1111/jcmm.16936. Epub 2021 Oct 19. PMID: 34664400

116. Jonasch E, Donskov F, Iliopoulos O, **Rathmell WK**, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SH, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R. Belzutifan (MK-6482) for von Hippel-Lindau Disease-associated renal cell carcinoma. *New England Journal of Medicine*. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425. PMID: 34818478.
117. Tucker MD, Brown LC, Chen YW, Kao C, Hirshman N, Kinsey EN, Ancell KK, Beckermann KE, Davis NB, McAlister R, Schaffer K, Armstrong AJ, Harrison MR, George DJ, **Rathmell WK**, Rini BI, Zhang T. Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. *Biomark Res*. 2021 Nov 3;9(1):80. doi: 10.1186/s40364-021-00334-4. PMID: 34732251; PMCID: PMC8564988.
118. Reisman BJ, Guo H, Ramsey HE, Wright MT, Reinfeld BI, Ferrell PB, Sulikowski GA, **Rathmell WK**, Savona MR, Plate L, Rubinstein JL, Bachmann BO. Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase. *Nat Chem Biol*. 2022 Apr;18(4):360-367. doi: 10.1038/s41589-021-00900-9. PMID: 34857958.
119. Glass EB, Hoover AA, Bullock KK, Madden MZ, Reinfeld BI, Harris W, Parker D, Hufnagel DH, Crispens MA, Khabele D, **Rathmell WK**, Rathmell JC, Wilson AJ, Giorgio TD, Yull FE. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. *BMC Cancer*. 2022 May 6;22(1):497. doi: 10.1186/s12885-022-09612-2. PMID: 35513776; PMCID: PMC9074180.
120. Haake SM, Plosa EJ, Kropski JA, Venton LA, Reddy A, Bock F, Chang BT, Luna AJ, Nabukhotna K, Xu ZQ, Prather RA, Lee S, Tanjore H, Polosukhin VV, Viquez OM, Jones A, Luo W, Wilson MH, **Rathmell WK**, Massion PP, Pozzi A, Blackwell TS, Zent R. Ligand-independent integrin beta1 signaling supports lung adenocarcinoma development. *JCI Insight*. 2022 Jun 28:e154098. doi: 10.1172/jci.insight.154098. Epub ahead of print. PMID: 35763345.
121. Hapke R, Venton L, Rose KL, Sheng Q, Reddy A, Prather R, Jones A, **Rathmell WK**, Haake SM. SETD2 regulates the methylation of translation elongation factor eEF1A1 in clear cell renal cell carcinoma. *Kidney Cancer J*. 2022;6(3):179-193. doi: 10.3233/kca-220009. Epub 2022 Nov 18. PMID: 36684483; PMCID: PMC9851421.
122. Voss K, Sewell AE, Krystofiak ES, Gibson-Corley KN, Young AC, Basham JH, Sugiura A, Arner EN, Beavers WN, Kunkle DE, Dickson ME, Needle GA, Skaar EP, **Rathmell WK**, Ormseth MJ, Major AS, Rathmell JC. Elevated transferrin receptor impairs T cell metabolism and function in systemic lupus erythematosus. *Sci Immunol*. 2023 Jan 13;8(79):eabq0178. doi: 10.1126/sciimmunol.abq0178. Epub 2023 Jan 13. PMID: 36638190; PMCID: PMC9936798.
123. Beebout CJ, Robertson GL, Reinfeld BI, Blee AM, Morales GH, Brannon JR, Chazin WJ, **Rathmell WK**, Rathmell JC, Gama V, Hadjifrangiskou M. Uropathogenic *Escherichia coli* subverts mitochondrial metabolism to enable intracellular bacterial pathogenesis in urinary tract infection. *Nat Microbiol*. 2022 Sep;7(9):1348-1360. doi: 10.1038/s41564-022-01205-w. Epub 2022 Aug 22. PMID: 35995841.
124. Baregamian N, Sekhar KR, Krystofiak ES, Vinogradova M, Thomas G, Mannoh E, Solórzano CC, Kiernan CM, Mahadevan-Jansen A, Abumrad N, Freeman ML, Weiss VL, Rathmell JC, **Rathmell WK**. Engineering functional 3-dimensional patient-derived

- endocrine organoids for broad multiplatform applications. *Surgery*. 2023 Jan;173(1):67-75. PMID: 36400581.
125. Sekhar KR, Codreanu SG, Williams OC, Rathmell JC, **Rathmell WK**, McLean JA, Sherrod SD, Baregamian N. Metabolism of parathyroid organoids. *Front Endocrinol (Lausanne)*. 2023 Jul 10;14:1223312. doi: 10.3389/fendo.2023.1223312. PMID: 37492197; PMCID: PMC10364603.
  126. Wang-Bishop L, Kimmel BR, Ngwa VM, Madden MZ, Baljon JJ, Florian DC, Hanna A, Pastora LE, Sheehy TL, Kwiatkowski AJ, Wehbe M, Wen X, Becker KW, Garland KM, Schulman JA, Shae D, Edwards D, Wolf MM, Delapp R, Christov PP, Beckermann KE, Balko JM, **Rathmell WK**, Rathmell JC, Chen J, Wilson JT. STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy. *Sci Immunol*. 2023 May 12;8(83):eadd1153. doi: 10.1126/sciimmunol.add1153. Epub 2023 May 5. PMID: 37146128; PMCID: PMC10226150.
  127. Mason FM, Kounlavong ES, Tebeje AT, Dahiya R, Guess T, Khan A, Vlach L, Norris SR, Lovejoy CA, Dere R, Strahl BD, Ohi R, Ly P, Walker CL, **Rathmell WK**. SETD2 safeguards the genome against isochromosome formation. *Proc Natl Acad Sci U S A*. 2023 Sep 26;120(39):e2303752120. doi: 10.1073/pnas.2303752120. Epub 2023 Sep 18. PMID: 37722039; PMCID: PMC10523680.
  128. Oldan JD, Schroeder JA, Hoffman-Censits J, **Rathmell WK**, Milowsky MI, Solnes LB, Nimmagadda S, Gorin MA, Khandani AH, Rowe SP. PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers. *PET Clin*. 2024 Jan 9:S1556-8598(23)00099-8. doi: 10.1016/j.cpet.2023.12.006. Epub ahead of print. PMID: 38199916.
  129. Abbott KL, Ali A, Reinfeld BI, Deik A, Subudhi S, Landis MD, Hongo RA, Young KL, Kunchok T, Nabel CS, Crowder KD, Kent JR, Madariaga MLL, Jain RK, Beckermann KE, Lewis CA, Clish CB, Muir A, **Rathmell WK**, Rathmell J, Vander Heiden MG. Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability. *Elife*. 2024 May 24;13:RP95652. doi: 10.7554/eLife.95652. PMID: 38787918; PMCID: PMC11126308.
  130. Walmer RW, Ritter VS, Sridharan A, Kasoji SK, Altun E, Lee E, Olinger K, Wagner S, Radhakrishna R, Johnson KA, **Rathmell WK**, Qaqish B, Dayton PA, Chang EH. The Performance of Flash Replenishment Contrast-Enhanced Ultrasound for the Qualitative Assessment of Kidney Lesions in Patients with Chronic Kidney Disease. *J Clin Med*. 2023 Oct 12;12(20):6494. doi: 10.3390/jcm12206494. PMID: 37892632; PMCID: PMC10607866.
  131. Wolf MM, Madden MZ, Arner EN, Bader JE, Ye X, Vlach L, Tigue ML, Landis MD, Jonker PB, Hatem Z, Steiner KK, Gaines DK, Reinfeld BI, Hathaway ES, Xin F, Tantawy MN, Haake SM, Jonasch E, Muir A, Weiss VL, Beckermann KE, **Rathmell WK**, Rathmell JC. VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis. *J Clin Invest*. 2024 Apr 15;134(8):e173934. doi: 10.1172/JCI173934. PMID: 38618956; PMCID: PMC11014672.
  132. Maldonado E, **Rathmell WK**, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. A Phase II Trial of the WEE1 Inhibitor

- Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). *Cancer Res Commun*. 2024 Jul 1;4(7):1793-1801. doi: 10.1158/2767-9764.CRC-24-0213. PMID: 38920407; PMCID: PMC11264598.
133. Bader JE, Wolf MM, Lupica-Tondo GL, Madden MZ, Reinfeld BI, Arner EN, Hathaway ES, Steiner KK, Needle GA, Hatem Z, Landis MD, Faneuff EE, Blackman A, Wolf EM, Cottam MA, Ye X, Bates ME, Smart K, Wang W, Pinheiro LV, Christofides A, Smith D, Boussiotis VA, Haake SM, Beckermann KE, Wellen KE, Reinhart-King CA, Serezani CH, Lee CH, Aubrey C, Chen H, **Rathmell WK**, Hasty AH, Rathmell JC. Author Correction: Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. *Nature*. 2024 Jul;631(8022):E16. doi: 10.1038/s41586-024-07794-2. Original PMID: 38867043, Erratum PMID: 38982216.
134. Bacigalupa ZA, Arner EN, Vlach LM, Wolf MM, Brown WA, Krystofiak ES, Ye X, Hongo RA, Landis M, Amason EK, Beckermann KE, **Rathmell WK**, Rathmell JC. HIF-2 $\alpha$  expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma. *J Clin Invest*. 2024 Jun 17;134(12):e164249. doi: 10.1172/JCI164249. PMID: 38941296; PMCID: PMC11178540.
135. Heintzman DR, Sinard RC, Fisher EL, Ye X, Patterson AR, Elasy JH, Voss K, Chi C, Sugiura A, Rodriguez-Garcia GJ, Chowdhury NU, Arner EN, Krystofiak ES, Mason FM, Toudji YT, Steiner KK, Khan W, Olson LM, Jones AL, Hong HS, Bass L, Beier KL, Deng W, Lyssiotis CA, Newcomb DC, Bick AG, **Rathmell WK**, Wilson JT, Rathmell JC. Subset-specific mitochondrial stress and DNA damage shape T cell responses to fever and inflammation. *Sci Immunol*. 2024 Sep 20;9(99):eadp3475. doi: 10.1126/sciimmunol.adp3475. Epub 2024 Sep 20. PMID: 39303018.
136. Kimmel BR, Arora K, Chada NC, Bharti V, Kwiatkowski AJ, Finkelstein JE, Hanna A, Arner EN, Sheehy TL, Pastora LE, Yang J, Pagendam HM, Stone PT, Hargrove-Wiley E, Taylor BC, Hubert LA, Fingleton BM, Gibson-Corley KN, May JC, McLean JA, Rathmell JC, Richmond A, **Rathmell WK**, Balko JM, Wilson JT. Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody-STING agonist conjugates. *Nat Biomed Eng*. 2025 Jun 11. doi: 10.1038/s41551-025-01400-0. Epub ahead of print. PMID: 40500332.
137. Arner EN, Jennings EQ, Crooks DR, Ricketts CJ, Wolf MM, Cottam MA, Fisher-Gupta EL, Lang M, Maio N, Shibata Y, Krystofiak ES, Vlach LM, Hatem Z, Blatt AM, Heintzman DR, Sewell AE, Hathaway ES, Steiner KK, Ye X, Schaefer S, Bacigalupa ZA, Linehan WM, Beckermann KE, Mason FM, Idrees K, **Rathmell WK**, Rathmell JC. Impaired oxidative phosphorylation drives primary tumor escape and metastasis. *bioRxiv* [Preprint]. 2025 Jan 9:2025.01.08.631936. doi: 10.1101/2025.01.08.631936. PMID: 39829901; PMCID: PMC11741308.

Consortium Manuscripts (peer reviewed)

1. **Cancer Genome Atlas Research Network**. Comprehensive genomic characterization of squamous cell lung cancers. *Nature*. 489(7417):519-25, 2012. PMID: 22960745. Collaborator. \*Indexed as Kimryn Rathmell, W.
2. **The Cancer Genome Atlas Network**. Comprehensive molecular portraits of human breast tumours. *Nature*. 490(7418):61-70, 2012. PMID: 23000897. Collaborator. \*Indexed as Kimryn Rathmell, W.

3. **Cancer Genome Atlas Research Network**, Integrated genomic characterization of endometrial carcinoma. *Nature*. 497:67-73, 2013. PMID: 23636398. \*Collaborator, indexed as W. Rathmell or Kimryn Rathmell.
4. **Cancer Genome Atlas Research Network**. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*. 2014 513(7517):202-9. PMCID: PMC 4170219.
5. **Cancer Genome Atlas Research Network**. Comprehensive molecular profiling of lung adenocarcinoma. *Nature*. 2014 Jul 31;511(7511):543-50. PMID: 25079552
6. **Cancer Genome Atlas Research Network**. Integrated genomic characterization of papillary thyroid carcinoma. *Cell*. 2014 159(3):676-90. PMCID: PMC4243044
7. Parfenov M, Peadarallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R; **Cancer Genome Atlas Research Network**. Characterization of HPV and host genome interactions in primary head and neck cancers. *Proc. Natl Acad. Sci. U S A*. 2014 111(43):15544-9. PMCID PMC4217452.
8. **Cancer Genome Atlas Research Network**, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhi R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T Jr, Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R,

Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG Jr, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, **Rathmell WK**, Rotin D, Scarpaccia L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *N Engl J Med*. 2015 Jun 25;372(26):2481-98. PMID: 26061751

9. **Cancer Genome Atlas Network**. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*. 2015 Jan 29;517(7536):576-82. PMID: PMC4311405. Selected for cover.
10. **Cancer Genome Atlas Network**. Genomic Classification of Cutaneous Melanoma. *Cell*. 2015 Jun 18;161(7):1681-96. PMID: 26091043
11. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA; **TCGA Research Network**, Perou CM. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell*. 2015 Oct 8;163(2):506-19. PMID: 26451490
12. **Cancer Genome Atlas Research Network**. The Molecular Taxonomy of Primary Prostate Cancer. *Cell*. 2015 Nov 5;163(4):1011-25. PMID: 26544944
13. Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB; **Cancer Genome Atlas Research Network**, Weinstein JN, Zhang J, Akbani R, Levine DA. Integrated Molecular Characterization of Uterine Carcinosarcoma. *Cancer Cell*. 2017 Mar 13;31(3):411-423 PMID: 28292439
14. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Peadarallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; **Cancer Genome Atlas Network**, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. : Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. *Cell Rep*. 2017 Mar 14;18(11):2780-2794 PMID: 28297679
15. **Cancer Genome Atlas Research Network**. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. *Cell*. 2017 Jun 15;169(7):1327-1341 PMID: 28622513

16. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Peadamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; **Cancer Genome Atlas Network**, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. *Cell Rep.* 2017 Jun 27;19(13):2878-2880. PMID: 28658632.
17. **Cancer Genome Atlas Research Network** Integrated genomic characterization of oesophageal carcinoma. *Nature.* 2017 2017 Jan 12;541(7636):169-175. PMID:28052061
18. **Cancer Genome Atlas Research Network.** Integrated genomic and molecular characterization of cervical cancer. *Nature.* 2017 Mar 16;543(7645):378-384. PMID: 28112728
19. **Cancer Genome Atlas Research Network.** Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. *Cancer Cell.* 2017 Aug 14;32(2):185-203.e13. PMID: 28810144
20. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Peadamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; **TCGA Research Network**, Weinstein JN, Kwiatkowski DJ, Lerner SP. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. *Cell.* 2017 Oct 19;171(3):540-556.e25. PMID: 28988769
21. **Cancer Genome Atlas Research Network.** Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. *Cell.* 2017 Nov 2;171(4):950-965.e28. PMID: 29100075
22. Ellrott K, Bailey MH, Saksena G, Covington KR, Kandath C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M, Sofia HJ, Hutter C, Getz G, Wheeler D, Ding L; MC3 Working Group; **Cancer Genome Atlas Research Network.** Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. *Cell Syst.* 2018 Mar 28;6(3):271-281.e7. PMID:29596782
23. Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C; **Cancer Genome Atlas Network.** Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. *Cell Syst.* 2018 Mar 28;6(3):282-300.e2. PMID:29596783
24. Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N; **Cancer Genome Atlas Research Network**, Sanchez Y, Greene CS. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. *Cell Rep.* 2018 Apr 3;23(1):172-180.e3. PMID:29617658
25. Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J; **Cancer Genome Atlas Research Network**, Shmulevich I, Rao AUK, Lazar AJ, Sharma A, Thorsson V. Spatial Organization and Molecular Correlation of Tumor-

- Infiltrating Lymphocytes Using Deep Learning on Pathology Images. *Cell Rep.* 2018 Apr 3;23(1):181-193.e7. PMID:29617659
26. Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Gevaert O, Prunello M, Shen H, Anur P, Chen J, Cheng H, Hayes DN, Bullman S, Pedamallu CS, Ojesina AI, Sadeghi S, Mungall KL, Robertson AG, Benz C, Schultz A, Kanchi RS, Gay CM, Hegde A, Diao L, Wang J, Ma W, Sumazin P, Chiu HS, Chen TW, Gunaratne P, Donehower L, Rader JS, Zuna R, Al-Ahmadie H, Lazar AJ, Flores ER, Tsai KY, Zhou JH, Rustgi AK, Drill E, Shen R, Wong CK; **Cancer Genome Atlas Research Network**, Stuart JM, Laird PW, Hoadley KA, Weinstein JN, Peto M, Pickering CR, Chen Z, Van Waes C. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. *Cell Rep.* 2018 Apr 3;23(1):194-212.e6. PMID:29617660
  27. Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H; **Cancer Genome Atlas Research Network**, Piwnicka-Worms H, Ma L, Liang H. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. *Cell Rep.* 2018 Apr 3;23(1):213-226.e3. PMID:29617661
  28. Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ; Fusion Analysis Working Group; **Cancer Genome Atlas Research Network**, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. *Cell Rep.* 2018 Apr 3;23(1):227-238.e3. PMID:29617662
  29. Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, Shen Y, Karimi M, Chen H, Kim P, Jia P, Shinbrot E, Zhang S, Liu J, Hu H, Bailey MH, Yau C, Wolf D, Zhao Z, Weinstein JN, Li L, Ding L, Mills GB, Laird PW, Wheeler DA, Shmulevich I; **Cancer Genome Atlas Research Network**, Monnat RJ Jr, Xiao Y, Wang C. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. *Cell Rep.* 2018 Apr 3;23(1):239-254.e6. PMID:29617664
  30. Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, Zhang H, Zhao Z, Marchand C, Weinstein JN; **Cancer Genome Atlas Research Network**, Bathe OF, Liang H. Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. *Cell Rep.* 2018 Apr 3;23(1):255-269.e4. PMID: 29617665
  31. Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Climente-González H, Chai S, Wang F, Varghese R, Huang M, Liang WW, Wyczalkowski MA, Sengupta S, Li Z, Payne SH, Fenyö D, Miner JH, Walter MJ; **Cancer Genome Atlas Research Network**, Vincent B, Eyras E, Chen K, Shmulevich I, Chen F, Ding L. Systematic Analysis of Splice-Site-Creating Mutations in Cancer. *Cell Rep.* 2018 Apr 3;23(1):270-281.e3. PMID:29617666
  32. Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG; **Cancer Genome Atlas Research Network**, Buonamici S, Yu L. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. *Cell Rep.* 2018 Apr 3;23(1):282-296.e4. PMID:29617667

33. Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS; **Cancer Genome Atlas Research Network**, Sood AK, Gunaratne PH, Sumazin P. Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. *Cell Rep*. 2018 Apr 3;23(1):297-312.e12. PMID: 29617668
34. Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ; **Cancer Genome Atlas Research Network**, Cherniack AD, Beroukheim R, Meyerson M. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. *Cancer Cell*. 2018 Apr 9;33(4):676-689.e3. PMID:29622463
35. Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; **Cancer Genome Atlas Research Network**, Weinstein JN, Mills GB, Levine DA, Akbani R. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. *Cancer Cell*. 2018 Apr 9;33(4):690-705.e9. PMID:29622464
36. Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S; **Cancer Genome Atlas Research Network**, Xie W, Yang D. lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. *Cancer Cell*. 2018 Apr 9;33(4):706-720.e9. PMID: 29622465
37. Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, Willis JE, Wang KK, McCall SJ, Mishra L, Ojesina AI, Bullman S, Peadarallu CS, Lazar AJ, Sakai R; **Cancer Genome Atlas Research Network**, Thorsson V, Bass AJ, Laird PW. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. *Cancer Cell*. 2018 Apr 9;33(4):721-735.e8 PMID:29622466
38. Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM; **Cancer Genome Atlas Network**, Stuart JM, Benz CC, Laird PW. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. *Cell*. 2018 Apr 5;173(2):291-304.e6. PMID:29625048
39. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandath C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; **Cancer Genome Atlas Research Network**, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic Signaling Pathways in The Cancer Genome Atlas. *Cell*. 2018 Apr 5;173(2):321-337.e10. PMID: 29625050
40. Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwińska P, Mazurek S, Mishra L, Heyn

- H, Krasnitz A, Godwin AK, Lazar AJ; **Cancer Genome Atlas Research Network**, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wiznerowicz M. Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. *Cell*. 2018 Apr 5;173(2):338-354.e15. PMID:29625051
41. Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlihan KE, Jayasinghe R, Wang LB, Zhou DC, Liu D, Cao S, Kim YW, Koire A, McMichael JF, Huchtagowder V, Kim TB, Hahn A, Wang C, McLellan MD, Al-Mulla F, Johnson KJ; **Cancer Genome Atlas Research Network**, Lichtarge O, Boutros PC, Raphael B, Lazar AJ, Zhang W, Wendl MC, Govindan R, Jain S, Wheeler D, Kulkarni S, Dipersio JF, Reimand J, Meric-Bernstam F, Chen K, Shmulevich I, Plon SE, Chen F, Ding L. Pathogenic Germline Variants in 10,389 Adult Cancers. *Cell*. 2018 Apr 5;173(2):355-370.e14. PMID: 29625052
  42. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; **Cancer Genome Atlas Research Network**, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell*. 2018 Apr 5;173(2):371-385.e18. PMID: 29625053
  43. Chen H, Li C, Peng X, Zhou Z, Weinstein JN; **Cancer Genome Atlas Research Network**, Liang H. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. *Cell*. 2018 Apr 5;173(2):386-399.e12. PMID: 29625054
  44. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V; **Cancer Genome Atlas Research Network**, Hu H. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell*. 2018 Apr 5;173(2):400-416.e11.
  45. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Peadamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE; **Cancer Genome Atlas Research Network**, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L. The Immune Landscape of Cancer. *Immunity*. 2018 Apr 17;48(4):812-830.e14. PMID: 29628290
  46. Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sánchez-Vega F, Pluta J, Pyle LC, Mehra R, Reuter VE, Godoy G, Jones J, Shelley CS, Feldman DR, Vidal DO, Lessel D, Kulis T, Cárcano FM, Leraas KM, Lichtenberg TM, Brooks D, Cherniack AD, Cho J, Heiman DI, Kasaian K, Liu M, Noble MS, Xi L, Zhang H, Zhou W, Zenklusen JC, Hutter CM, Felau I, Zhang J, Schultz N, Getz G, Meyerson M, Stuart JM; **Cancer Genome Atlas Research Network**, Akbani R, Wheeler DA, Laird PW, Nathanson KL, Cortessis VK, Hoadley KA. Integrated Molecular

- Characterization of Testicular Germ Cell Tumors. *Cell Rep.* 2018 Jun 12;23(11):3392-3406. PMID: 29898407
47. Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C; **Cancer Genome Atlas Research Network**, Rättsch G. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. *Cancer Cell.* 2018 Aug 13;34(2):211-224.e6. PMID: 30078747
  48. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavitai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H; MC3 Working Group; **Cancer Genome Atlas Research Network**, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell.* 2018 Aug 9;174(4):1034-1035. PMID: 30096302
  49. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; **Cancer Genome Atlas Research Network**, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- $\beta$  Superfamily. *Cell Syst.* 2018 Sep 14. PMID: 30268436
  50. Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB; **Cancer Genome Atlas Research Network**, Camargo F, Liang H. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. *Cell Rep.* 2018 Oct 30;25(5):1304-1317.e5.
  51. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; **Cancer Genome Atlas Research Network**, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- $\beta$  Superfamily. *Cell Syst.* 2018 Oct 24;7(4):422-437.e7 PMID: 30268436
  52. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Mokrab Y, Newman AM, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CS; **Cancer Genome Atlas Research Network**, Lazar AJ, Serody

- JS, Demicco EG, Disis ML, Vincent BG, Shmulevich I. The Immune Landscape of Cancer. *Immunity*. 2019 Aug 20;51(2):411-412. PMID: 31433971
53. ICGC/**TCGA Pan-Cancer Analysis of Whole Genomes Consortium**. Pan-cancer analysis of whole genomes. *Nature*. 2020 Feb;578(7793):82-93. doi: 10.1038/s41586-020-1969-6. Epub 2020 Feb 5. PMID: 32025007; PMCID: PMC7025898.
54. Li CH, Prokopec SD, Sun RX, Yousif F, Schmitz N; PCAWG Tumour Subtypes and Clinical Translation, Boutros PC; **PCAWG Consortium**. Sex differences in oncogenic mutational processes. *Nat Commun*. 2020 Aug 28;11(1):4330. doi: 10.1038/s41467-020-17359-2. PMID: 32859912; PMCID: PMC7455744.
55. Bailey MH, Meyerson WU, Dursi LJ, Wang LB, Dong G, Liang WW, Weerasinghe A, Li S, Li Y, Kelso S; MC3 Working Group; PCAWG novel somatic mutation calling methods working group, Saksena G, Ellrott K, Wendl MC, Wheeler DA, Getz G, Simpson JT, Gerstein MB, Ding L; **PCAWG Consortium**. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. *Nat Commun*. 2020 Sep 21;11(1):4748. doi: 10.1038/s41467-020-18151-y. Erratum in: *Nat Commun*. 2020 Nov 30;11(1):6232. PMID: 32958763; PMCID: PMC7505971.
56. Bratslavsky G, Mendhiratta N, Daneshvar M, Brugarolas J, Ball MW, Metwalli A, Nathanson KL, Pierorazio PM, Boris RS, Singer EA, Carlo MI, Daly MB, Henske EP, Hyatt C, Middleton L, Morris G, Jeong A, Narayan V, **Rathmell WK**, Vaishampayan U, Lee BH, Battle D, Hall MJ, Hafez K, Jewett MAS, Karamboulas C, Pal SK, Hakimi AA, Kutikov A, Iliopoulos O, Linehan WM, Jonasch E, Srinivasan R, Shuch B. Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. *Cancer*. 2021 Nov 1;127(21):3957-3966. doi: 10.1002/cncr.33679. Epub 2021 Aug 3. PMID: 34343338.

#### Review Articles (peer reviewed)

1. **Rathmell, WK** and Godley, PA. Renal cell carcinoma. *Curr Opin Oncol*, 16: 247-252, 2004. PMID: 15069321
2. **Rathmell, WK**, Godley, PA, and Rini, BI. Renal cell carcinoma. *Curr Opin Oncol*, 17: 261-267, 2005. PMID: 15818172
3. **Rathmell, WK** and Simon, MC. VHL: oxygen sensing and vasculogenesis. *J Thromb Haemost*, 3: 2627-2632, 2005. PMID: 15975138
4. **Rathmell, WK**, Wright, TM, and Rini, BI. Molecularly targeted therapy in renal cell carcinoma. *Expert Rev Anticancer Ther*, 5: 1031-1040, 2005. PMID: 16336094
5. Rini, BI, Campbell, SC, and **Rathmell, WK**. Renal cell carcinoma. *Curr Opin Oncol*, 18: 289-296, 2006. PMID: 16552243
6. **Rathmell, WK**, Martz, CA, and Rini, BI. Renal cell carcinoma. *Curr Opin Oncol*, 19: 234-240, 2007. PMID: 17414642
7. Rini, BI and **Rathmell, WK**. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. *Clin Cancer Res*, 13: 741s-746s, 2007. PMID: 17255303
8. **Rathmell, WK** and Chen, S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. *Expert Rev Anticancer Ther*, 8: 63-73, 2008. PMID: 18095884

9. Rini, BI, **Rathmell, WK**, and Godley, P. Renal cell carcinoma. *Curr Opin Oncol*, 20: 300-306, 2008. PMID: 18391630
10. Cowey, CL and **Rathmell, WK**. Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma. *Expert Opinion on Drug Discovery* 3(3): 311-327, 2008. PMID: 20648240
11. Cowey, CL and **Rathmell, WK**. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. *Curr Oncol Rep*, 11: 94-101, 2009. PMID: 19216840
12. **Rathmell, WK**, Cowey, CL, and Fielding, J. Reply: Is objective response rate completely objective in kidney cancer? Improving radiographic assessment of targeted therapy in renal cell carcinoma. *Urology*, 2009. PMID: 19931124
13. **Rathmell, WK**, Pruthi, RS, Wallen, E. Neoadjuvant treatment of renal cell carcinoma. *Urol. Onc.* 2010. 28(1):69-73 PMID: 20123351
14. **Rathmell, WK**, and Godley, PA. Updates in Renal Cell Carcinoma. *Current Opinion in Oncology*. 2010;22(3):250-6. PMID: 20154618
15. Brannon, AR, **Rathmell, WK**. Renal cell carcinoma, where will the state of the art lead us? *Current Oncology Reports*. 2010;12(3):193-201 PMID: 20425079
16. Hacker, KE, **Rathmell, WK**. Emerging molecular classification in RCC: implications for drug development. *Targeted Oncology*. 5(2):75-84, 2010. PMID: 20645016
17. Rasmussen, N and **Rathmell, WK**. Looking beyond inhibition of VEGF/mTOR: Emerging targets for renal cell carcinoma drug development. *Current Clinical Pharmacology*. 2011 Aug;6(3):199-206. PMID: 21470103
18. Oosterwijk E, **Rathmell WK**, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Beldegrun A. Basic research in kidney cancer. *Eur Urol*. 2011 Oct;60(4):622-33. PMID: 21741760
19. Khandani AH, **Rathmell WK**. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. *Semin Nucl Med*. 2012, 42(4):221-30. PMID: 22681671
20. Jonasch, E, Futreal, PA, Bailey, S, Kim, WY, Atkins, M, Sharma, P, Davis, IJ, Walker, CL, **Rathmell, WK**. State of the Science: update on renal cell carcinoma. *Mol Cancer Res*. 2012, 10(7):859-80. PMID: 22638109; PMC3399969
21. Linehan WM, **Rathmell WK**. Kidney cancer. *Urol Oncol*. 2012 30(6):948-51. PMID: 23218074
22. Keefe SM, Nathanson KL, **Rathmell WK**. The molecular biology of renal cell carcinoma. *Semin Oncol*. 2013 Aug;40(4):421-8. PMID: 23972705
23. **Rathmell, WK**, Brooks SA, Parker JS, Nielsen ME. Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Cheville's Letter to the Editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma. *Eur Urol* 2014;66:77-84. *Eur Urol*. 2014 Jul 15. S0302-2838(14)00630-7. PMID: 25037640
24. Chism, DD, **Rathmell, WK**. Seeing the Forest for the Trees: Kidney Oncogenomes Relate to Therapeutic Outcomes. *Clin Cancer Res*. 2014 20(7):1721-3 PMC4077661
25. Jonasch, E, Gao, JJ, **Rathmell WK**. Renal Cell Carcinoma. *BMJ*. 2014 Nov 10;349:g4797. PMID: 25385470

26. Debebe Z, **Rathmell WK**. Ror2 as a Therapeutic Target in Cancer. *Pharmacol Ther*. 2015 150:143-8. PMID: 25614331
27. Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, **Rathmell WK**, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, Chen YC, Honoki K, Fujii H, Georgakilas AG, Newsheen S, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich B, Yang X, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Halicka D, Mohammed SI, Azmi AS, Bilstrand A, Keith WN, Jensen LD. Broad targeting of angiogenesis for cancer prevention and therapy. *Semin Cancer Biol*. 2015 Suppl:S224-43 PMID: 25600295
28. Hu Z, Brooks SA, Dormoy V, Hsu CW, Hsu HY, Lin LT, Massfelder T, **Rathmell WK**, Xia M, Al-Mulla F, Al-Temaimi R, Amedei A, Brown DG, Prudhomme KR, Colacci A, Hamid RA, Mondello C, Raju J, Ryan EP, Woodrick J, Scovassi AI, Singh N, Vaccari M, Roy R, Forte S, Memeo L, Salem HK, Lowe L, Jensen L, Bisson WH, Kleinstreuer N Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. *Carcinogenesis*. 2015 Jun;36 Suppl 1:S184-202. Review. PMID: 26106137
29. Goodson WH 3rd, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglolle CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami G, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Kim Lyerly H, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP Sr, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzio LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Leonart M, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson P, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom S, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, **Rathmell WK**, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z. Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. *Carcinogenesis*. 2015 Jun;36 Suppl 1:S254-96. Review. PMID: 26106142

30. **Rathmell KW\***, Chen F, Creighton CJ. Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies. *Oncoscience*. 2015 Feb 20;2(2):81-90. Review. PMID: 25859550 \*Index error.
31. Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AM, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Fingleton MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Newsheem S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, **Rathmell WK**, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HP, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HM, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. *Semin Cancer Biol*. 2015 35 Suppl:S276-304. PMID: 26590477
32. Chang EH, Chong WK, Kasoji S, Dayton PA, **Rathmell WK**. Management of Indeterminate Cystic Kidney Lesions: Review of Contrast-Enhanced Ultrasound as a Diagnostic Tool. *Urology*. 2015 Oct 16. Jan; 87:1-10. PMID: 26483268
33. Chism DD, **Rathmell WK**. Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer. *Nat Rev Nephrol*. 2016 Jun;12(6):317-8. PMID: 27108841 PMCID: PMC4871728
34. Haake SM, Weyandt JD, **Rathmell WK**. Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas. *Mol Cancer Res*; 2016 14(7); 589-98. PMID: 27330105 PMCID: PMC4955752
35. Haake SM, **Rathmell WK**. Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making? *Cancer*. 2017 Jan 1;123(2):200-209. PMID: 27861752
36. Siska PJ, Beckermann KE, **Rathmell WK**, Haake SM. Strategies to overcome therapeutic resistance in renal cell carcinoma. *Urol Oncol*. 2017 Mar;35(3):102-110. PMID: 28089416

37. Reinfeld BI, **Rathmell WK**. Untangling ccRCC prognosis with SLINKY. *Oncotarget*. 2017 Mar 21;8(12):18620-18621. PMID: 28220033
38. Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, **Rathmell WK**. Renal Medullary Carcinoma: Establishing Standards in Practice. *J Oncol Pract*. 2017 Jul;13 PMID: 28697319
39. Weyandt JD, Thompson CB, Giaccia AJ, **Rathmell WK**. Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. *Am Soc Clin Oncol Educ Book*. 2017;37:825-832.. Review. PMID: 28561705
40. Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, Olsen C, Kim J, Taylor AM, Cherniack AD, Akbani R, Suphavitai C, Nagarajan N, Stuart JM, Mills GB, Wyczalkowski MA, Vincent BG, Hutter CM, Zenklusen JC, Hoadley KA, Wendl MC, Shmulevich L, Lazar AJ, Wheeler DA, Getz G; **Cancer Genome Atlas Research Network**. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. *Cell*. 2018 Apr 5;173(2):305-320.e10. PMID: 29625049
41. Ghatalia P, **Rathmell WK**. Systematic Review: ClearCode 34 - A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC). *Kidney Cancer*. 2018;2(1):23-29. PMID: 30320241
42. de Cubas AA, **Rathmell WK**. Epigenetic modifiers: activities in renal cell carcinoma. *Nat Rev Urol*. 2018 Oct;15(10):599-614. Review. PMID: 30030490
43. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, **Rathmell WK**, Tannir NM. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients with Renal Medullary Carcinoma. *Clin Genitourin Cancer*. 2018 Sep 12. pii: S1558-7673(18)30384-7. PMID: 30287223
44. **Rathmell WK**, Rathmell JC, Linehan WM. Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. *J Clin Oncol*. 2018 Oct 29;JCO2018792309. doi: 10.1200/JCO.2018.79.2309. [Epub ahead of print]
45. Chappell JC, Payne LB, **Rathmell WK**. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. *J Clin Invest*. 2019 Feb 1;129(2):442-451. PMID: 30614813 PMCID: PMC6355237
46. Moslehi J, **Rathmell WK**. The 2019 Nobel Prize honors fundamental discoveries in hypoxia response. *J Clin Invest*. 2020 Jan 2;130(1):4-6. PMID: 31763994
47. Bacigalupa ZA, **Rathmell WK**. Beyond glycolysis: Hypoxia signaling as a master regulator of alternative metabolic pathways and the implications in clear cell renal cell carcinoma. *Cancer Lett*. 2020 Oct 1;489:19-28. doi: 10.1016/j.canlet.2020.05.034. Epub 2020 Jun 5. PMID: 32512023; PMCID: PMC7429250.
48. Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, **Rathmell WK**, Daniels AB, Jonasch E, Spiess PE; International VHL Surveillance Guidelines Consortium-Renal Committee. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL

- disease. *World J Urol.* 2020 Sep 16. doi: 10.1007/s00345-020-03441-3. Epub ahead of print. PMID: 32936333.
49. Jonasch E, Walker CL, **Rathmell WK**. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. *Nat Rev Nephrol.* 2020 Nov 3. doi: 10.1038/s41581-020-00359-2. Epub ahead of print. PMID: 33144689.
  50. Rini B, Abel EJ, Albiges L, Bex A, Brugarolas J, Bukowski RM, Coleman JA, Drake CG, Figlin RA, Futreal A, Hammers H, Powles T, **Rathmell WK**, Ricketts CJ, Turajlic S, Wood CG, Leibovich BC. Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. *Clin Genitourin Cancer.* 2020 Nov 14:S1558-7673(20)30234-2. doi: 10.1016/j.clgc.2020.10.005. PMID: 33358149.
  51. Rathmell JC, **Rathmell WK**. Pushing the boundaries with collision collaboration: the marriage of ideas. *J Clin Invest.* 2021 Jan 19;131(2):e145964. PMID: 33463534; PMCID: PMC7810468.
  52. Choueiri TK, Atkins MB, Bakouny Z, Carlo MI, Drake CG, Jonasch E, Kapur P, Lewis B, Linehan WM, Mitchell MJ, Pal SK, Pels K, Poteat S, **Rathmell WK**, Rini BI, Signoretti S, Tannir N, Uzzo R, Wood CG, Hammers HJ. Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. *J Natl Cancer Inst.* 2021 Mar 1;113(3):234-243. PMID: 32359162; PMCID: PMC7936057.
  53. Reinfeld BI, **Rathmell WK**, Kim TK, Rathmell JC. The therapeutic implications of immunosuppressive tumor aerobic glycolysis. *Cell Mol Immunol.* 2021 Jul 8 doi: 10.1038/s41423-021-00727-3. PMID: 34239083
  54. Chahoud J, McGettigan M, Parikh N, Boris RS, Iliopoulos O, **Rathmell WK**, Daniels AB, Jonasch E, Spiess PE; International VHL Surveillance Guidelines Consortium-Renal Committee. Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. *World J Urol.* 2021 Jul. doi: 10.1007/s00345-020-03441-3. PMID: 32936333
  55. Bratslavsky G, Mendhiratta N, Daneshvar M, Brugarolas J, Ball MW, Metwalli A, Nathanson KL, Pierorazio PM, Boris RS, Singer EA, Carlo MI, Daly MB, Henske EP, Hyatt C, Middleton L, Morris G, Jeong A, Narayan V, **Rathmell WK**, Vaishampayan U, Lee BH, Battle D, Hall MJ, Hafez K, Jewett MAS, Karamboulas C, Pal SK, Hakimi AA, Kutikov A, Iliopoulos O, Linehan WM, Jonasch E, Srinivasan R, Shuch B. Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. *Cancer.* 2021 Aug 3. doi: 10.1002/cncr.33679. PMID: 34343338
  56. Choueiri TK, Albiges L, Atkins MB, Bakouny Z, Bratslavsky G, Braun DA, Haas NB, Haanen JBAG, Hakimi AA, Jewett MAS, Jonasch E, Kaelin WG Jr, Kapur P, Labaki C, Lewis B, McDermott DF, Pal SK, Pels K, Poteat S, Powles T, **Rathmell WK**, Rini BI, Signoretti S, Tannir NM, Uzzo RG, Hammers HJ. From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. *Clin Cancer Res.* 2022 Mar 1;28(5):831-839. doi: 10.1158/1078-0432.CCR-21-3238. PMID: 34965942.
  57. Gallagher EJ, Rockey DC, Kontos CD, Vyas JM, Brass LF, Hu PJ, Isales CM, Ajjjola OA, **Rathmell WK**, Conlin PR, Baiocchi RA, Kazmierczak BI, Akabas MH, Williams CS. Pearls of wisdom for aspiring physician-scientist residency applicants and program directors. *JCI Insight.* 2022 Mar 22;7(6):e158467. doi: 10.1172/jci.insight.158467. PMID: 35315364; PMCID: PMC8986063.

58. **Rathmell WK**, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina AM, Rose TL, Siva S, Zaorsky NG, Zhang T, Qamar R, Kungel TM, Lewis B, Singer EA. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. *J Clin Oncol*. Sep 1;40(25):2957-2995. doi: 10.1200/JCO.22.00868. Epub 2022 Jun 21. PMID: 35728020.
59. Williams CS, **Rathmell WK**, Carethers JM, Harper DM, Lo YMD, Ratcliffe PJ, Zaidi M. A global view of the aspiring physician-scientist. *Elife*. 2022 Sep 13;11:e79738. doi: 10.7554/eLife.79738. PMID: 36098684; PMCID: PMC9470153.
60. Wolf MM, Rathmell WK, de Cubas AA. Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. *Nat Rev Nephrol*. 2023 Jul;19(7):440-450. doi: 10.1038/s41581-023-00700-5. Epub 2023 Mar 27. PMID: 36973495.
61. Hantel A, Spence R, Camacho P, Bradbury AR, Denburg AE, Jagsi R, Moy B, **Rathmell WK**, Rosenberg AR, Symington B, Marron JM, Peppercorn J. ASCO Ethical Guidance for the Practical Management of Oncology Drug Shortages. *J Clin Oncol*. 2024 Jan 20;42(3):358-365. doi: 10.1200/JCO.23.01941. Epub 2023 Dec 7. PMID: 38061010.
62. Singer EA, Rumble RB, **Rathmell WK**, Van Veldhuizen PJ; Management of Metastatic Renal Clear Cell Cancer Guideline Expert Panel. Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update. *J Clin Oncol*. 2023 Nov 20;41(33):5184-5186. doi: 10.1200/JCO.23.01977. Epub 2023 Oct 9. PMID: 37812756.
63. Hantel A, Spence R, Camacho P, Bradbury AR, Denburg AE, Jagsi R, Moy B, **Rathmell WK**, Rosenberg AR, Symington B, Marron JM, Peppercorn J. ASCO Ethical Guidance for the Practical Management of Oncology Drug Shortages. *J Clin Oncol*. 2024 Jan 20;42(3):358-365. doi: 10.1200/JCO.23.01941. Epub 2023 Dec 7. PMID: 38061010.
64. Oldan JD, Schroeder JA, Hoffman-Censits J, **Rathmell WK**, Milowsky MI, Solnes LB, Nimmagadda S, Gorin MA, Khandani AH, Rowe SP. PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers. *PET Clin*. 2024 Apr;19(2):197-206. doi: 10.1016/j.cpet.2023.12.006. Epub 2024 Jan 9. PMID: 38199916.
65. Bianchi DW, Brennan PF, Chiang MF, Criswell LA, D'Souza RN, Gibbons GH, Gilman JK, Gordon JA, Green ED, Gregurick S, Hodes RJ, Kilmarx PH, Koob GF, Koroshetz WJ, Langevin HM, Lorsch JR, Marrazzo JM, Pérez-Stable EJ, **Rathmell WK**, Rodgers GP, Rutter JL, Simoni JM, Tromberg BJ, Tucci DL, Volkow ND, Woychik R, Zenk SN, Kozlowski E, Peterson RS, Ginsburg GS, Denny JC. The All of Us Research Program is an opportunity to enhance the diversity of US biomedical research. *Nat Med*. 2024 Feb;30(2):330-333. doi: 10.1038/s41591-023-02744-3. PMID: 38374344.
66. Geiger AM, Jaffee EM, Berger MS, Brown CL, **Rathmell WK**, Bertagnolli MM. An orientation to the US National Cancer plan for the research community. *J Natl Cancer Inst*. 2024 Jun 7;116(6):789-794. doi: 10.1093/jnci/djae037. PMID: 38427849.
67. **Rathmell WK**. Using the National Cancer Plan to Drive Innovation in Cancer Research. *Cancer Discov*. 2024 Apr 4;14(4):555-558. doi: 10.1158/2159-8290.CD-24-0223. PMID: 38571429.
68. Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhir R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, Hakimi AA, Henske EP, Hsieh JJ, Ho TH, Kanchi RS, Krishnan B, Kwiatkowski DJ, Liu W, Merino MJ,

Mills GB, Myers J, Nickerson ML, Reuter VE, Schmidt LS, Shelley CS, Shen H, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Vincent BG, Vocke CD, Wheeler DA, Yang L, Kim WY, Robertson AG; Cancer Genome Atlas Research Network; Spellman PT, **Rathmell WK**, Linehan WM. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Rep*. 2024 Apr 23;43(4):113063. doi: 10.1016/j.celrep.2023.113063. Epub 2024 Apr 4. Erratum for: *Cell Rep*. 2018 Apr 3;23(1):313-326.e5. doi: 10.1016/j.celrep.2018.03.075. PMID: 38578829.

69. Fahey CC, **Rathmell WK**. Clinical Trials-Real-World Data to Build a Future for Our Patients. *J Clin Oncol*. 2024 Jun 20;42(18):2117-2120. doi: 10.1200/JCO.24.00374. Epub 2024 May 10. PMID: 38728618.

#### Books and chapters

1. **Rathmell, WK**, Chu, G. Mechanisms for DNA double-strand break repair in eukaryotic cells. In Nickolof, J.A., Hoekstra, M.F. (eds.) DNA damage and repair, Vol. 2: DNA repair in higher eukaryotes, Humana Press, pp. 299-316, 1998
2. **Rathmell, WK**. VHL Gene: Clinical Implications, In ASCO Education Book, pp. 239-244, 2007.
3. **Rathmell, WK**, Stadler, WM, Rini, BI. Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer, ASCO Education Book, 7 typed pages, 2008.
4. **Rathmell, WK** and Godley, P. Testicular Cancer. In Netter's Internal Medicine. 2nd Edition. Runge, M. and Greganti, A. (eds.). pp. 614-622, 2008.
5. **Rathmell, WK** and Rini, BI. Biologic and Clinical Implications of VEGF Activity in Renal Cell Carcinoma. In Renal Cell Carcinoma, Bukowski, R., Motzer, R., and Figlin, R. (eds.). pp. 99-118. 2008.
6. Amin, C and **Rathmell, WK**. Angiogenesis Biology in Metastatic Renal Cell Carcinoma. In Renal Cell Carcinoma, Rini, B. and Campbell, S. (eds.). pp. 191-202, 2009.
7. Rini, BI and **Rathmell, WK**. Vascular Endothelial Growth Factor Ligand-Binding Agents. In Renal Cell Carcinoma, Rini, B. and Campbell, S. (eds.). pp. 203-210, 2009.
8. Reddy, A, Kronek, L-P, Brannon, AR, Seiler, M, Ganesan, S, **Rathmell, WK**, Bhanot, G. Predicting Cancer Survival Using Expression Patterns. In Medical Biostatistics for Complex Diseases. Emmert-Streib, F. and Dehmer, M. (eds.). pp. 305-330. 2010
9. Oosterwijk, E, Belldegrun, A, Brannon, AR, Finley, DS, Junker, K, Pouliot, F, **Rathmell, WK** and Uemura, H. Basic Research in Kidney Cancer. In Kidney Cancer. Eds. Z. Kirkali and P. Mulders. 1st EAU-ICUD International Consultation on Kidney Cancer, Barcelona, 2010. Edition 2011. Pages 31-45
10. Li, M and **Rathmell, WK**. Biomarkers for renal cell carcinoma. In Renal cell carcinoma: Principles and Practice. Eds. Primo Lara and Eric Jonasch. 2011.
11. Haake, SM and **Rathmell, WK**. The biology of renal cell carcinoma. In Emerging Cancer Therapeutics: Renal Cancer. Eds. Walter Stadler and Jame Abraham. 2011. Pages 1-20.
12. Li, M and **Rathmell, WK**. Biomarkers in renal cell carcinoma, ASCO Education Book, 2011.
13. Arreola, A and **Rathmell, WK**. Biology of RCC (VEGF, mTOR, immune aspects). In Renal cell carcinoma: clinical management. Eds. Brian Rini and Stephen Campbell. 2012

14. **Rathmell, WK.** HIF biology in renal cell carcinoma. In *Renal Cell Carcinoma: Biology, Prognostic Factors, and Therapeutic Targets*. Eds. Robert Figlin, Brian Rini, and W. Kimryn Rathmell. 2012
15. Chism, DD and **Rathmell, WK.** Prognostic and Predictive Biomarkers in Renal Cell Carcinoma (RCC). In *Renal Cell Carcinoma*. Ed. Nizar Tannir. 2014
16. Ferguson, JE, Wallen, EM, and **Rathmell, WK.** Kidney Cancer. In *9th Manual of Clinical Oncology*. 2014
17. Rose, T and **Rathmell, WK** Biomarkers for Renal Cell Carcinoma. In *Renal Cell Carcinoma: Principles and Practice, 2nd ed.* Eds. Primo Lara and Eric Jonasch. 2015.
18. Lim, A and **Rathmell, WK** Chromophobe Renal Cell Carcinoma. In *Prognostic and Predictive Biomarkers in Renal Cell Carcinoma, 2<sup>nd</sup> Edition*. Ed. Nizar Tannir. 2018.

Un-refereed reviews, perspectives, editorials

1. **Rathmell, WK.,** and Van Dyke, T., Keystone Symposia, Mouse Models of Human Cancer Meeting Review. *Investigational Drugs Database*. Thomson Current Drugs Online, 2004
2. Draznin, J. Kidney cancer. An Interview with Dr. Kimryn Rathmell, [www.oncolink.com](http://www.oncolink.com) July, 2004.
3. **Rathmell, WK.** ASCO Updates. Focus on Fellows and Junior Faculty, Participation in the annual meeting. 2005.
4. **Rathmell, WK.** and Shaw R. mTOR: An Emerging Pathway in Cancer, Novartis Internal Training Module. 2008.
5. **Rathmell, WK.** Biomarkers guide choice in systemic treatment. *Kidney Cancer Journal*. 6(1): 208-212, 2008
6. **Rathmell, WK.** Comment on autophagy related to VHL gene as a strategy to develop cancer treatments, NPR Morning Edition. 2008
7. **Rathmell, WK.** The importance of HIF in clear cell renal cell carcinoma. *Kidney Cancer Journal*. 7(2): 303-305, 2009.
8. **Rathmell, WK** Tumor Genomics Program. ASCO University. 2014.  
<http://university.asco.org/tumor-genomics-program>
9. **Rathmell, WK** Making Strides Against a Rare Disease: Renal Medullary Carcinoma in Focus. OnLive. June 8, 2017
10. Martin DM, **Rathmell WK,** Tavazoie SF. Balancing dual demands on the physician-scientist workforce. *J Clin Invest*. 2018 Jul 16. [Epub ahead of print]. PMID: 30010627
11. Marr KA, **Rathmell WK,** Hawley JB, Guth KD. Empowering ASCI's support of physician-scientists through stronger institutional connections. *J Clin Invest*. 2019 Apr 1;129(4):1516-1518. PMID: 30932915 PMCID: PMC6436849
12. **Rathmell WK.** Disruptions in the realm of medical science. *J Clin Invest*. 2020 Jun 1;130(6):2731-2732. doi: 10.1172/JCI139912. PMID: 32478677; PMCID: PMC7260009.
13. Levine RL, **Rathmell WK.** COVID-19 impact on early career investigators: a call for action. *Nat Rev Cancer*. 2020 Jul;20(7):357-358. doi: 10.1038/s41568-020-0279-5. PMID: 32503987; PMCID: PMC7273376.
14. Bacigalupa ZA, **Rathmell WK.** Upcycling the TCA cycle-rewiring tumour-associated fibroblasts. *Nat Metab*. 2021 Nov;3(11):1439-1440. doi: 10.1038/s42255-021-00473-w. PMID: 34764458.

15. Gaines DK, **Rathmell WK**. Spatial models of tumour evolution. *Nat Ecol Evol*. 2022 Jan;6(1):26-27. doi: 10.1038/s41559-021-01584-z. PMID: 34949818.
16. Arner EN, **Rathmell WK**. Mutation and tissue lineage lead to organ-specific cancer. *Nature*. 2022 Jun;606(7916):871-872. doi: 10.1038/d41586-022-01535-z. PMID: 35676353.
17. Wolf MM, **Rathmell WK**, de Cubas AA. Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. *Nat Rev Nephrol*. 2023 Jul;19(7):440-450. doi: 10.1038/s41581-023-00700-5. Epub 2023 Mar 27. PMID: 36973495.
18. **Rathmell WK**. Learning to pivot: developing talent and a championship team. *Trans Am Clin Climatol Assoc*. 2023;133:81-92. PMID: 37701598; PMCID: PMC10493740.
19. **Rathmell WK**, Beg S. Leading Change in Cancer Clinical Research, Because Our Patients Can't Wait. *Cancer Currents Blog*, May 31, 2024 <https://www.cancer.gov/news-events/cancer-currents-blog/2024/clinical-trials-cancer-inviting-innovation>
20. **Rathmell WK**, Gallahan D. Growing the Cancer Research Pipeline by Expanding Opportunities. *Cancer Currents Blog*, August 29, 2024 <https://www.cancer.gov/news-events/cancer-currents-blog/2024/cancer-research-r15-grants-expanding-workforce>
21. Singer DS, **Rathmell WK**. Tumour atlases enable researchers to navigate through cancers. *Nature*. Research Briefing. October 30, 2024
22. Becker W, **Rathmell WK**. Vaccines in cancer treatment and prevention: the time is now. *J Clin Invest*. 2025 Jul 1;135(13):e195673. doi: 10.1172/JCI195673. PMID: 40590227; PMCID: PMC12208550.

#### Meeting papers

1. Reddy, A., Brannon, AR, Seiler, M, Irgon, J, Ljungberg, B, Zhao, H, Brooks, JD, **Rathmell, WK**, Ganesan, S, Bhanot, G. A Predictor for Survival in Intermediate Grade Clear Cell Renal Cell Carcinoma. BioComp '09 Proceedings. 2009.

#### Thesis, PhD Biophysics:

1. **Rathmell, WK**. "Ku and DNA/PK in the repair of DNA double strand breaks", 1996, Stanford University

#### Selected Events and Presentations as Director, National Cancer Institute, U.S.A.

1. Events on behalf of the Biden Administration and White House:
  - a. Dr. Jill Biden announcement of Cancer Navigation at Wake Forest University, Charlotte, NC, February 2024
  - b. White House Conference on Cervical Cancer, Washington DC, February 2024
  - c. QUAD initiative U.S.-India Dialogue. New Delhi, India, August 2024 (attended virtually)
2. *NCI Director's Updates for FACA Board Meetings* (held 3x per year): National Cancer Advisory Board, NCI Board of Scientific Advisors, NCI Clinical Trials Advisory Committee, NCI Board of Scientific Counselors, NCI Council of Research Advocates, Frederick National Labs Advisory Committee
3. AACR. Plenary, Fireside Chat with President Dr. Phillip Greenberg, Panelist, April 2024

4. ASCO. Plenary, NCI Director's Update, June 2024
5. AAI. Fireside chat – what will it take to end cancer as we know it, May 4 2024
6. *Cancer CEO Roundtable*. Clinical Trials Panel Discussion, March 2024; Keynote, September 2024
7. *National Academy of Sciences/National Academy of Medicine*. State of the U.S. Biomedical and Health Research Enterprise, October 2024
8. *Cancer G7 Conference*. Paris, France May 2024
9. *International Agency for Research on Cancer (WHO)*, Lyon, France, May 2024
10. *Visits to NCORP Sites*: Bronx VA, Bronx Montefiore, Kansas Masonic Clinical Trials Alliance
11. National MD-PhD Student Conference, Keynote speaker, Keystone, CO, July 2024
12. *Stanford University Cancer Biology Student Day*, January 2024
13. Kansas University Comprehensive Cancer Center, with Senator Jerry Moran, August 2024
14. *University of Chicago Comprehensive Cancer Center 50<sup>th</sup> Anniversary and Educational Symposium*, August 2024
15. University of Illinois – Chicago, *MSTP Distinguished Speaker*, September 2024
16. Georgetown University Cancer Center, September 2024
17. *Iowa Coalition Cancer Summit*, Keynote, October 2024
18. *Stan Korsmeyer Memorial lecture*, Washington University St. Louis, October 2024
19. *JCI 100<sup>th</sup> Anniversary*, Keynote, October 2024
20. AACI Keynote, October 2024
21. *Friends of Cancer Research Annual Meeting*, Keynote, November 2024
22. *National Coalition for Cancer Survivorship*, November 2024
23. *Milken Symposium on early onset tumors*, November 2024
24. *Women in Science Panel* with Astronaut Kate Robins, November 2024
25. *Perspectives in Progress*, Stanford University, November 2024

**Invited Presentations after 2025:**

1. University of Pennsylvania, John Morgan Medicine Grand Rounds, January 25, 2025
2. Baylor College of Medicine, Dan Duncan Cancer Center, February 17, 2025
3. Medical University of South Carolina, February 21, 2025
4. Johns Hopkins and Lustgarten Foundation – Power of Persistence, March 7, 2025
5. American Cancer Society Medal of Honor Acceptance, March 8, 2025
6. Yale Cancer Center – 17<sup>th</sup> Annual Paul Calabresi lectureship, March 25, 2025
7. Emory University Physician Scientist Symposium, April 4, 2025
8. ASCI/AAP/APSA Joint Meeting. Korsmeyer Award Lecture April 25, 2025
9. ASCI/AAP/APSA Joint Meeting. Fireside Chat. April 26, 2025
10. ASCI/AAP/APSA Joint Meeting. PSTP program keynote. April 27, 2025
11. VUMC MSTP Retreat Keynote, June 28, 2025
12. Kidney Cancer Research Summit, July 17, 2025
13. UNC Lineberger 50<sup>th</sup> Anniversary Symposium, September 9, 2025
14. UNC MD-PhD Program 25<sup>th</sup> Anniversary Celebration, October 16, 2025

**Invited Presentations prior to 2024:**

1. Functional and Tissue Specific Effects of VHL mutations, Abramson Cancer Center Symposium, University of Pennsylvania, September 2002.
2. Molecular Models of VHL Disease, Pharmacology Seminar, Duke University, October 2002.
3. Models of VHL Disease and Renal Cell Carcinoma, Lineberger Cancer Center Seminar Series, University of North Carolina at Chapel Hill, October 2002.
4. VHL Mutations in Tissue Specific Tumorigenesis, Division of Oncology, Washington University School of Medicine, October 2002.
5. VHL Mutations in Human Cancers, Ingram Cancer Center, Vanderbilt University, Nov 2002.
6. VHL Mutations in Human Cancers, Lineberger Cancer Center Symposia, University of North Carolina at Chapel Hill, September 2003.
7. Multidisciplinary Advances in the Treatment of Genitourinary Cancers, University of North Carolina at Chapel Hill, February 2004.
8. Advances in the Treatment of Advanced Renal Cell Carcinoma. Symposium on 112.
9. Genetic events in the development of renal cell carcinoma, MSTP Seminar Series, University of North Carolina at Chapel Hill, September 24, 2004.
10. VHL: Oxygen sensing and molecular targeting, Forbeck Foundation Forum on Molecularly Targeted Therapy. Hilton Head, SC. November 2004.
11. VHL: Oxygen sensing and vasculogenesis, Curriculum in Genetics and Molecular Biology Seminar Series. University of North Carolina, January 7, 2005.
12. Animal Modeling of RCC, Genetics Core Meeting, University of North Carolina, Feb 2005.
13. Renal Cell Carcinoma, NorthEast Medical Center, Concord, NC, February 22, 2005.
14. Update on Treatment of Advanced Renal Cell Carcinoma, Symposium of Multidisciplinary Advances in the Treatment of Genitourinary Cancers, Chapel Hill, June 17, 2005.
15. ASCO Update on Prostate Cancer and Renal Cell Carcinoma. North Carolina Oncology Association semiannual meeting, Greensboro, NC. August 6, 2005
16. Genetic Determinants of Renal Cell Carcinoma. Forbeck Junior Forum. Lake Geneva, WI, September 17, 2005.
17. Mouse Models of Kidney Cancer. Kidney Cancer Association Annual Meeting (submitted abstract selected for oral presentation). Chicago, IL. October 21, 2005.
18. Advances in the Treatment of Advanced Renal Cell Carcinoma. Landes Symposium on Urologic Cancer. Chapel Hill, NC. June 23, 2006.
19. Structure and Function of VHL in Renal Cell Carcinoma. 3rd International Congress on Kidney and Bladder Cancer. Orlando, FL. August 3, 2006
20. Genetic Determinants in the Development of Renal Cell Carcinoma. Forbeck Junior Forum. Lake Geneva, WI, September 16, 2006.
21. Genetic Events in the Development of Renal Cell Carcinoma. UNC Genetics Retreat. Wrightsville Beach, NC. September 23, 2006.
22. Recent Advances in Understanding the Pathogenesis of Kidney Cancer. Current Trends in Genitourinary Malignancies. New York, NY. November 18, 2006.
23. Of mice and men: understanding VHL pathogenesis. Cleveland Clinic, Cleveland, OH. December 5, 2006.

24. Of mice and men: VHL pathogenesis in renal cell carcinoma. University of New Mexico, Albuquerque, NM. December 12, 2006.
25. VHL Gene: Clinical Implications, ASCO Annual Meeting, Expanded Education session. Chicago, IL. June 1, 2007.
26. Renal Cell Carcinoma, Clinical Update. Wake Medical Center, and Dorthea Dix Medical Center. Raleigh, NC. June 12, 2007.
27. Renal Cell Carcinoma, Lessons learned from Tyrosine Kinase Inhibitors, one year from FDA approval. Landes Genitourinary Malignancy Symposium. Chapel Hill, NC June 15, 2007
28. Basic Biology for Clinicians. Third World Congress of Oncology. San Francisco, CA September 9, 2007
29. Ror2, a novel kinase in RCC. Forbeck Junior Forum. Lake Geneva, WI, September 14, 2007
30. Renal Cell Carcinoma. NC Pharmacology Assoc. Winston-Salem, NC. February 28, 2008
31. Neoadjuvant Sorafenib for Advanced Renal Cell Carcinoma. Bayer Investigators Meeting. Chicago, IL. April 25, 2008.
32. Preclinical and Prognostic Biomarkers of Renal Cell Carcinoma. ASCO Annual Meeting. Chicago, IL. June 1, 2008.
33. Molecular Characteristics of Renal Cell Carcinoma Contributing to Response to Targeted Therapy. Rutgers University BIOMaps Symposium. New Brunswick, NJ. August 3, 2008.
34. HIF1 vs HIF2 interplay in renal cell carcinoma. Forbeck Junior Forum. Lake Geneva, WI. September 12, 2008
35. How does cytoreductive nephrectomy help? The science behind tumor reduction surgery. 7th Annual Kidney Cancer Association Meeting. Chicago, IL. September 26, 2008.
36. Renal Cell Carcinoma: a new era of targeted therapy. CME accredited seminars. Maine Medical Center. Silver Springs MD, Birmingham, AL, Laurinberg, NC, Hendersonville, NC, October, 2008-February, 2009.
37. Grand Rounds: Renal Cell Carcinoma. Cornell University, October 13, 2008.
38. Renal Cell Carcinoma. University of Cincinnati, November 6, 2008.
39. Combinations of targeted therapy and immunotherapy in renal cell carcinoma. Immunotherapy Conference 2008. Havana, Cuba. November 10, 2008.
40. Neoadjuvant use of TKI prior to nephrectomy. Society for Urologic Oncology. Bethesda, MD. December 4, 2008.
41. Renal cell carcinoma and response to targeted therapy. University of Kansas, Topeka. CME update. January 16, 2009.
42. Renal cell carcinoma: update 2009. University of Nevada Reno. Grand Rounds. Reno, NV. January, 2009.
43. Renal cell carcinoma, what every internist needs to know. Internal Medicine Symposium, Chapel Hill, NC. March 20, 2009.
44. Emerging biomarkers for renal cell carcinoma. Kidney Cancer Association, Chicago II, September 24, 2009
45. Adjunctive therapy for renal cell carcinoma. Nexavar Investigators meeting. Chicago, IL. October 8, 2009

46. Renal Cell Carcinoma: Morning Report (CME series): High Point Regional Health System, High Point, NC, East Carolina Medical Center, New Bern, NC, Dorn VA Medical Center, Columbia, SC, John B Amos Cancer Center, Columbus, GA, Zimmer Cancer Center, Wilmington, NC, Forsythe Medical Center, Winston-Salem, NC, October 2009-January 2010.
47. Clear cell RCC: not so clear any more. Ohio State University, Molecular Carcinogenesis and Chemoprevention Seminar. Columbus, OH, December 17, 2009
48. Renal Cell Carcinoma. Walter Reed Army Hospital. Washington DC. February 19, 2010
49. Cancer Biology Program Seminar Series. Duke Comprehensive Cancer Center. Durham, NC. February 26, 2010
50. ccRCC, not so clear anymore. Stanford Cancer Center Seminar Series. Stanford, CA. March 4, 2010
51. Renal Cell Carcinoma Update. Queens Hospital Grand Rounds. New York, NY. March 15, 2010
52. Biomarkers for Renal Cell Carcinoma. AACR Meeting, 2010. Washington DC. April 20 2010
53. Selecting Targeted Therapy for RCC, CME Series, June, 2010-present. University of Michigan VAMC, Ann Arbor, MI, Charles George VA Medical Center, Asheville, NC., VAMC Clarksville, WV (scheduled), VAMC Somerset, PA (scheduled), Karmanos Cancer Center, Detroit, MI (scheduled)
54. Molecular Stratification of Renal Cell Carcinoma. Dana Farber Cancer Center Kidney Cancer 5th Annual Symposium. Boston, MA. August 12, 2010.
55. Neoadjuvant treatment of Renal cell carcinoma. Fourth Cambridge Conference on Innovations and Challenges in Renal Cancer. Cambridge, MA. August 13, 2010.
56. Understanding Molecular Stratification of Renal Cell Carcinoma. MD Anderson Cancer Center GU Grand Rounds. August 19, 2010.
57. Segregating subtypes of clear cell renal cell carcinoma. 1st Western New York and Southern Ontario Kidney Cancer Symposium. Lewiston, NY. October 8, 2010.
58. Dissecting complex signatures from renal cell carcinoma. Van Andel Research Institute Cancer Seminar Series. Grand Rapids, MI. February 23, 2011.
59. Molecular Classification of Renal Cell Carcinoma. 1st annual MD Anderson Kidney Cancer Research Symposium. Houston, TX. March 25, 2011.
60. Biology of Clear Cell Renal Cell Carcinoma. AACR Session. Orlando, FL. April 24, 2011.
61. Renal Cell Carcinoma. Biomarkers and Clinical Practice. ASCO Education Session. Chicago, IL. June 4, 2011.
62. TCGA Update in Renal Cell Carcinoma. Kidney Cancer Association Annual Symposium. Chicago, IL. October 16, 2011.
63. Renal Cell Carcinoma: Molecular Markers and Neoadjuvant Therapy. Landes Symposium. Chapel Hill, NC. June 18, 2011.
64. Defining Molecular Subsets of Renal Cell Carcinoma. 16th Annual Congress on Molecular Oncology. Rhodes, Greece. October 7, 2011.
65. Ror2 Kinase in Renal Cell Carcinoma. FASEB Symposium on Kinases and Phosphatases. Snowmass, CO. July 20, 2011.

66. Epigenetics and VHL disease. VHL international conference. MD Anderson Cancer Center, Houston, TX. February 12, 2012
67. High throughput analysis of renal cancers. MD Anderson Cancer Center. Houston, TX. March 22, 2012
68. Clinical Subtypes of RCC. Princess Margaret Hospital and Cancer Center. Toronto, ON May 9, 2011
69. Clear Cell RCC Classification, Sunnybrook Cancer Center, University of Toronto, May 10, 2012
70. Classifications of RCC. 2nd Annual Western NY and Southern Ontario Kidney Cancer Meeting. Roswell Park. Buffalo, NY May 12, 2012
71. Next Steps in RCC Biology. Kidney Cancer Association Annual Meeting. Chicago, IL. October 6, 2012
72. Epigenetic Landscape of Renal Cell Carcinoma, Signaling Grand Rounds, Duke University, Durham, NC October 31, 2012
73. Translation of Genomic Findings to RCC Treatments. Society of Translational Medicine. Chapel Hill, NC. October 20, 2012.
74. SETD2 in RCC, Grand Rounds, University of Chicago, Chicago, IL. November 16, 2012
75. Unraveling RCC Heterogeneity. Society of Urologic Oncology Annual Meeting. Bethesda, MD. November 30, 2012.
76. Importing Heterogeneity into New Biomarker Studies. NCI Task Force Planning Meeting for RCC. Orlando, FL. February 16, 2013.
77. Moving forward with RCC Heterogeneity. MD Anderson SPORE Planning Meeting and External Advisory Board Meeting. Houston, TX. March 21, 2013.
78. RCC Translational Studies. UNC Pathology Grand Rounds. Chapel Hill, NC. March 21, 2013.
79. Translational Studies in RCC. Hettelman Award Lecture. Chapel Hill, NC. April 19, 2013.
80. Ethics Roundtable on Genomic Cancer Studies. ASCO Satellite Luncheon. Chicago, IL. May 31. 2013.
81. RCC Adjunctive Therapies Abstract Discussion Leader. ASCO. Chicago, IL. June 1. 2013.
82. ClearCode Risk Stratification of RCC. ASCO Poster Discussion Session. Chicago, IL. June 4, 2013.
83. Strategies for Negotiation as Physician-Scientist. MSTP Keystone Meeting. Keystone, CO. July 26, 2013.
84. Navigating the Two-Body Problem. With Jeff Rathmell. Duke MSTP Retreat. Wrightsville Beach, NC September 29, 2013.
85. Chromophobe Renal Cell Carcinoma. Society of Urologic Oncology. Bethesda, MD. Dec 2-3, 2013.
86. Doctors, Data, Disease. Institute for Pure and Applied Mathematics, UCLA. Feb 11-14, 2014.
87. Epigenetic Reprogramming in RCC. Fredrich Meisner Institute, Basel Switzerland, May 8 2014. Pending
88. Transcriptional processing in RCC. University of Zurich (ETH). Zurich, Switzerland, April 12, 2014.

89. Weissman Institute. Renal Cell Carcinoma Translational Opportunities. Rehovot, Israel July 2014, (seminar canceled due to political situation—meeting held by Skype).
90. RCC Genomics and Therapeutics. Novartis Pharmaceuticals, Basel, Switzerland. June 18 2014.
91. Transcriptomics of VHL disease. VHL Alliance International Meeting. Madrid, Spain. October, 2014
92. SETD2 Mutations in Clear Cell RCC. Society of Urologic Oncology, Bethesda, MD. December 2014.
93. Translational Studies in RCC. Vanderbilt Ingram Cancer Center. Nashville, TN. December 2014
94. Translational Studies in RCC. Cleveland Clinic. Cleveland, OH. February, 2015.
95. Using Kidney tissue to make disease assessment. Special conference on Acute Kidney Injury, NIDDK, Bethesda, MD, March 2015
96. Angiogenic and Metabolic Phenotypes in RCC. Cancer Metabolism. ChongQing, China. March 2015.
97. Comparison of kidney cancers using The Cancer Genome Atlas. Lineberger Symposium. Chapel Hill, NC April 2015
98. Epigenetics in Kidney Cancer. American Urologic Association. New Orleans, LA May 2015
99. Targeting Notch pathway to overcome resistance to anti-angiogenic therapy in RCC, MD Anderson Cancer Center, Ann. Kidney Cancer Symposium, Houston, TX, May 2015
100. Balancing the career of an MD-PhD. UNC MSTP Retreat. Wrightsville Beach, NC. Aug 2015.
101. New Directions in RCC, Forbeck Foundation Scholar Retreat, Lake Geneva, WI, Oct 2015
102. James Wilson Lectureship, University of Northern Iowa, Chemistry Department, Cedar Falls, IA, Oct 2015
103. What Nephrologists should know about kidney cancer. American Society of Nephrology. Sand Diego, CA. Nov 2015
104. Alterations in angiogenesis related to VHL mutation. Nanomedicine Symposium. Houston, TX. Jan 2016.
105. Translational Studies in RCC. Nephrology Faculty Series. Vanderbilt University. Jan 2016
106. Translational Studies in RCC. Cancer Biology Science Hour. Vanderbilt University. Feb 2016
107. ClearCode34, is it ready for prime time? Cancer Colloquium 2016. St. Andrews, Scotland. Feb 2016.
108. Chromatin and transcriptional regulation in RCC. Cancer Symposium. Duke-NUS Singapore. Mar 2016.
109. Forbeck Focus Meeting on Renal Medullary Carcinoma, Nashville, TN, April 2016
110. Translational Research at the Bioinformatic Edge. Schloss Dagstuhl, Wadern, Germany, June 2016
111. Vanderbilt Urology Conference. Renal Cell Carcinoma. Nashville, TN August 2016
112. Vanderbilt Medical Alumni. Translational studies in cancer. Nashville, TN October 21, 2016

113. Northwestern University Lurie Cancer Center Grand Rounds. Epigenetics of Kidney Cancer. Chicago, IL February 10, 2017
114. ASCO Annual Meeting. Education Session. Targeting Metabolism in Cancer. Chicago, IL. June 5, 2017
115. AACR Molecular Biology in Clinical Oncology (Faculty). Renal Cell Carcinoma. Aspen, Co. July 27, 2017
116. University of Colorado Health Science Center. RCC Genomics. September 2017
117. Mass General Hospital Cancer Series. Epigenetics in RCC. Boston, MA Nov 30, 2017
118. Cancer Center Grand Rounds, Indiana University, Indianapolis, IN Dec 8, 2017
119. Lineberger Comprehensive Cancer Center Seminar Series, SETD2 a dual function methyltransferase (or more?). Chapel Hill, NC January, 2018
120. Oklahoma University Cancer Center Seminar Series. RCC. Oklahoma City, OK March 9, 2018
121. Vanderbilt Nephrology Seminar. Kidney Cancer for Nephrologists. March, 2018
122. Emory Winship Cancer Center Seminar. Genomic Instability in RCC. Atlanta, GA June 7, 2018
123. University of Alabama Birmingham, Cancer Center Grand Rounds. September 10, 2018
124. VHL Alliance Annual Meeting (organizer and speaker). Houston, TX. October 6, 2018
125. Graceland updates on kidney cancer. Memphis, TN. November 9, 2018
126. Baylor College of Medicine, Cancer Center Seminar Series. Jan 7, 2019
127. MD Anderson Grand Rounds. Houston TX. January 14, 2019
128. Dana Farber Kidney SPORE seminar. January 7, 2019
129. Roswell Park Cancer Institute, Cancer Genetics External Seminar Series. Buffalo, NY. June 22, 2019
130. Madrid CNIO Research Council Distinguished Seminars Series. Madrid, Spain. March 8 2019
131. Virginia Tech Carilion Research Institute (VTCRI) *Distinguished Public Lecturer*. Roanoke, VA. Spring 2019
132. Kidney Cancer Association, Croatia, March 28-29, 2019
133. Oklahoma University Cancer Center Seminar, October 11, 2019
134. Dana Farber Cancer Center Urology Seminar Series, September 11, 2019
135. *Eugene P. Schonfeld Memorial Lecture*. Kidney Cancer Association International Meeting, Miami, FL. November 15, 2019
136. Vanderbilt University Medical Center, Setting a vision for the DOM, Spring 2020
137. Vanderbilt MSTP, Learning to Pivot, October 1, 2020
138. American Society of Nephrology, HIF is Noble and Nobel, November 7, 2020
139. Wistar Institute Distinguished Lectures in Cancer Research, November 24, 2020
140. Stanford University Cancer Center Frontiers in Oncology Seminar, February 16, 2021
141. Dana Farber Cancer Center, Kidney Cancer Seminar Series, April, 2021
142. UNC Chapel Hill, Medicine Grand Rounds, May 13, 2021
143. University of Chicago MSTP Retreat Keynote, June 24, 2021
144. AACR MBCO Faculty Speaker, July 2021
145. Emory Cancer Center, Elkin Lecture, September 17, 2021

146. Brown University Cancer Center Seminar Series, October 13, 2021
147. Dana Farber/MGH K12 Retreat Keynote, October 17, 2021
148. Kidney Cancer Association Annual Meeting, Career Development Panel (November 5, 2021)
149. Cancer Research Symposium, University of Cincinnati, (October 29, 2021)
150. University of Maryland Grand Rounds Speaker (January 18, 2021)
151. University of Chicago *Janet Rowley Lectureship* (March 1, 2021)
152. AACR 2022 Annual Meeting, Drug therapy for genetic disease (April 12, 2022)
153. Forbeck Forum: Histone methylation and cancer, co-chair (April 1, 2022)
154. AACR Molecular Biology in Clinical Oncology 2022, Snowmass, CO *Keynote* (July 2022)
155. Brazilian Society for Immunology 2022 Annual Meeting, Sao Paulo, BZ (pending September 2022)
156. Northwestern University Cancer Center Seminar (September 2022)
157. Columbia University, Grand Rounds (November 2022)
158. American Clinical and Climatological Association (October 2022)
159. Dana Farber GU-Oncology Seminar Series (October 2022)
160. National Academies, National Cancer Policy Forum on Immunotherapy Resistance in Cancer (November 2022)
161. University of Texas Southwestern, Cancer Center Seminar (December 2022)
162. International Kidney Cancer Symposium, Austin, TX Invited speaker (November 2022)
163. Baylor College of Medicine Bobby Alford Lecture (March 2023)
164. Stanford University, Department of Urology (April 2023)
165. AACR Kidney Cancer Special Topics Meeting, Invited speaker (June 2023)
166. MSKCC K12 Retreat Speaker, NY, NY (June 2023)
167. KidneyCAN Kidney Cancer Research Summit, Boston, MA (July 2023)
168. ASCI Scientific Sessions, virtual platform (September 2023)
169. International Kidney Cancer Symposium, Nashville, TN (November 2023)
170. Stanford University Cancer Biology, Stanford, CA (January 30, 2024)